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Glutamine synthetase (GS) converts glutamate and NH4+ to glutamine. GS is 42 
expressed by endothelial cells (ECs), but surprisingly shows negligible glutamine 43 
synthesizing activity at physiological glutamine levels. Nonetheless, genetic loss of 44 
GS in ECs impairs vessel sprouting during vascular development, while 45 
pharmacological GS blockade suppresses angiogenesis in ocular and inflammatory 46 
skin disease, only minimally affecting healthy adult quiescent ECs. This relies on 47 
inhibition of EC migration but not proliferation. Mechanistically, GS knockdown 48 
(GSKD) reduces membrane localization and activation of the GTPase RHOJ, while 49 
activating other Rho GTPases and Rho kinase (ROCK), thereby inducing actin 50 
stress fibers and impeding EC motility. ROCK inhibition rescues the GSKD EC 51 
migratory defect. Notably, GS is auto-palmitoylated and interacts with RHOJ to 52 
sustain RHOJ palmitoylation, membrane localization and activation. These findings 53 
highlight a novel molecular activity for GS, in addition to its glutamine synthesizing 54 
activity, in EC migration during pathological angiogenesis.  55 
Endothelial cells (ECs) line the lumen of blood vessels. Emerging evidence reveals that 56 
EC metabolism controls vessel sprouting (angiogenesis)1-3. While glutamine catabolism in 57 
ECs was recently characterized4, it remains undetermined if glutamine anabolism controls 58 
angiogenesis in vivo. Glutamine is a carbon and nitrogen donor for biomolecule production 59 
and is involved in redox homeostasis. Most cells take up glutamine and thus do not need 60 
to synthesize it. Nonetheless, certain cell types express glutamine synthetase (GS; also 61 
called glutamate-ammonia ligase; GLUL), the enzyme capable of de novo glutamine 62 
production from glutamate and ammonia in an ATP and Mg2+/Mn2+ requiring reaction. GS 63 
serves also another biochemical function, i.e. ammonia clearance, but this is best 64 
described for hepatocytes, astrocytes and muscle. ECs also express GS5, though its role 65 
and importance in angiogenesis remain puzzling, given that ECs are exposed to high 66 
plasma glutamine levels. Global GS deficiency causes embryonic lethality, presumably 67 
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due to the inability to detoxify ammonia6. GS deficiency in humans is extremely rare and 68 
leads to multi-organ failure with infant death7. If and how GS affects angiogenesis has 69 
never been analyzed. Here we characterized the role and importance of GS in vessel 70 
sprouting.  71 
VESSEL SPROUTING REQUIRES ENDOTHELIAL GS 72 
We checked GS expression in endothelial cells of the retinal microvasculature with a 73 
genetic GS reporter mouse (GS+/GFP mice with a nucleus-targeted GFP-lamin A fusion 74 
reporter transgene in the GS ORF of one allele6). GFP tracing in the postnatal day 5 (P5) 75 
retinal plexus, co-stained with the endothelial cell marker Isolectin B4 (IB4; red), revealed 76 
endothelial expression of GFP (and thus of GS) in the microvasculature (Fig. 1a).  77 
Human umbilical venous endothelial cells (further referred to as ECs) expressed GS to 78 
similar levels as human colon ECs, liver ECs, human umbilical arterial ECs and blood 79 
outgrowth ECs (BOECs), but to a lower level than lung ECs (Extended Data Fig. 1a). 80 
However, GS expression in ECs or isolated mouse liver ECs (mLiECs) was lower than in 81 
HEPG2 hepatocellular carcinoma cells or astrocytes (Extended Data Fig. 1a-c), known to 82 
highly express GS. Glutamine withdrawal (below physiological concentration of 0.6 mM) 83 
increased GS protein levels in ECs (Fig. 1b; Extended Data Fig. 1b), as previously 84 
documented for other cell types8.  85 
We intercrossed GSlox/lox mice with two different EC-specific tamoxifen inducible Cre driver 86 
lines, i.e. VE-cadherin(PAC)-CreERT2  and Pdgfb-CreERT2  mice to obtain respectively 87 
GSvECKO and GSpECKO mice. Correct recombination of the loxed GS allele was confirmed 88 
(Extended Data Fig. 1d-e) and caused an average 84% reduction of GS mRNA levels in 89 
mLiECs isolated from GSvECKO mice (Fig. 1c). In the neonatal retina, vascular plexi in P5 90 
GSvECKO mice showed hypobranching and reduced radial expansion, whereas vessel 91 
coverage by NG2+ pericytes and vessel regression (number of empty collagen IV+ 92 
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sleeves) were unaffected (Fig.1d-h, Extended Data Fig. 1f,g). However, the number of 93 
filopodia at the vascular front and of distal sprouts with filopodia, both parameters of EC 94 
migration, was lower in GSvECKO pups (Fig 1i-j). Furthermore, the complexity of the 95 
vasculature at the utmost leading front of the plexus was decreased as determined by 96 
counting the number of branches in distal sprouts (Extended Data Fig. 1h). In contrast, 97 
quantification of IB4+ EdU+ cells revealed no difference in the number of proliferating ECs 98 
(Fig. 1k-m; Extended Data Fig. 1i). Hypobranching was also observed in the dorsal dermal 99 
blood vasculature in E16.5 GSvECKO embryos (Fig. 1n-r). A similar retinal phenotype was 100 
observed in GSpECKO mice (Extended Data Fig. 1j-m). Thus, loss of endothelial GS causes 101 
vascular defects by impairing EC migration but not proliferation. 102 
The retinal vascular defect restored over time (Extended Data Fig. 1n-u) and at 6 weeks, 103 
GSvECKO animals (with GS deleted in ECs at P1-P3) did not show overt vascular defects 104 
(Extended Data Fig. 1v-ag). GSvECKO animals gained normal body weight, and blood 105 
biochemistry and hematological profiles were normal at 6 weeks (Extended Data Table 1). 106 
Vascular restoration may relate to the possibility that homozygous mutant ECs were 107 
outcompeted over time by residual wild type ECs, in which recombination did not occur (as 108 
documented in mice with endothelial loss of other key metabolic genes9) or because of 109 
other compensatory adaptations. Alternatively, the results raise the question if the effect of 110 
endothelial GS loss may be larger in growing (motile) ECs during vascular development 111 
than in quiescent (non-motile) ECs during adulthood in healthy conditions. 112 
We then explored if pharmacological blockade of GS with methionine sulfoximine (MSO), 113 
which irreversibly blocks its catalytic activity, reduced pathological angiogenesis. First, in 114 
the oxygen-induced model of retinopathy of prematurity (ROP)2,3, treatment of pups with 115 
MSO reduced the formation of pathological vascular tufts (Fig. 2a-c), while modestly 116 
increasing the vaso-obliterated area (Fig. 2d and Extended Data Fig. 1ah-ai). Second, we 117 
used the corneal micro-pocket assay (CPA) in mice with slow-release basic fibroblast 118 
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growth factor (bFGF) containing pellets as a model of corneal neovascularization. 119 
Inclusion of MSO in the pellet reduced formation of new CD31+ blood vessels in the 120 
otherwise avascular cornea (Fig. 2e-g). Finally, we used the imiquimod-based mouse 121 
model of inflammation-driven skin psoriasis and found a remarkable dose-dependent 122 
reduction of the CD105+ EC area upon topical treatment of the affected skin with MSO 123 
(Fig. 2h-l). Thus, pharmacological GS blockade inhibits pathological angiogenesis in the 124 
inflamed skin and in several eye disorders. 125 
SILENCING GS REDUCES EC MIGRATION 126 
We then used GS knockdown (GSKD) ECs (shRNA-mediated; >80% silencing; Extended 127 
Data Fig. 2a) in in vitro spheroid sprouting assays to assess vessel sprouting. GSKD 128 
reduced the number of sprouts per spheroid and the total sprout length (Fig. 3a,b,e,f). Re-129 
introduction of a shRNA resistant GS (rGSOE) rescued the sprouting defect (Extended data 130 
Fig. 2b-c). The sprouting defect in GSKD spheroids was maintained upon mitotic 131 
inactivation of ECs with mitomycin C (MitoC) (Fig. 3c-f), further suggesting an EC motility 132 
defect. In agreement, at physiological glutamine levels, GSKD did not affect EC proliferation 133 
(Fig. 3g). The sprouting defect was also not due to reduced EC viability or increased 134 
oxidative stress, or to changes in energy charge, glutathione or NADPH levels, glycolysis, 135 
glucose or glutamine oxidation, or oxygen consumption (Extended Data Fig. 2d-m). 136 
GSKD impaired migration in scratch-wound and Boyden chamber assays, even upon MitoC 137 
treatment, an effect that was rescued by re-introducing a shRNA-resistant GS (rGSOE) 138 
(Fig. 3h-i). Furthermore, sparsely seeded GSKD ECs had a reduced velocity of random 139 
movement (Fig. 3j; Supplemental videos 1 and 2) and a decreased lamellipodial area (Fig. 140 
3k-m). Comparable results were obtained with a second non-overlapping shRNA and a 141 
GS-specific siRNA (Extended Data Fig. 2a; Extended Data Fig. 3a-e).  142 
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The migration defects suggested that GSKD perturbed the remodeling of the actin 143 
cytoskeleton, necessary for cellular motility. Notably, we detected an increase in F-actin 144 
levels in GSKD ECs (Fig. 3n). A role of GS in cytoskeletal remodeling was further 145 
suggested by analyzing repolymerization of the actin cytoskeleton upon disruption with the 146 
F-actin polymerization inhibitor latrunculin B and subsequent wash-out. Latrunculin B 147 
perturbed the normal morphology of control and GSKD ECs (Fig. 3o-r). After wash-out, 148 
when control cells had rebuilt a normal actin cytoskeleton, GSKD ECs still had higher F-149 
actin levels, mainly originating from increased numbers of stress fiber bundles (Fig. 3s-u). 150 
GSKD did not alter α-tubulin levels (Fig. 3v; Extended data Fig. 4a-h).  151 
The increase in F-actin levels was also present in ECs, freshly isolated from MSO-treated 152 
mice (Extended data Fig. 4i-k), and in confluent GSKD ECs aligning a scratch wound in 153 
vitro (Extended data Fig. 4l-n). Confluent monolayer GSKD ECs displayed compromised 154 
junctional integrity (Extended data Fig. 4o-v). Functionally, this corresponded to a 155 
decrease in trans-endothelial electrical resistance (TEER) of GSKD ECs in vitro (Extended 156 
data Fig. 4w) and increased leakiness of inflamed (but not healthy) vessels in vivo 157 
(Extended data Fig. 4x-z).  158 
GLUTAMINE PRODUCTION BY ENDOTHELIAL GS  159 
To explore whether the migration defect was attributable to reduced de novo glutamine 160 
synthesis, we measured the glutamine synthesizing activity of GS by supplementing ECs 161 
with 15NH4Cl (Extended Data Fig. 5a). At a physiological concentration of 0.6 mM 162 
glutamine or higher, the glutamine producing activity of GS was negligible, approximating 163 
the level observed in ECs treated with MSO; it slightly increased only upon glutamine 164 
withdrawal, presumably to compensate for the lack of available glutamine (Fig. 4a). Similar 165 
results were obtained in medium containing dialyzed serum (Extended Data Fig. 5b). For 166 
further details see Supplementary Discussion 1 and Extended Data Fig. 5c-n. 167 
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To determine if the GSKD phenotype relied on the catalytic site of GS, we used previously 168 
reported concentrations of MSO10, which competes with glutamate in the catalytic site of 169 
GS and irreversibly blocks GS. MSO reduced EC spheroid sprouting, impaired EC 170 
migration in scratch-wound assays under MitoC treatment, decreased lamellipodial area, 171 
while increasing F-actin levels after latrunculin B wash-out but without affecting EC 172 
proliferation (Extended Data Fig. 5o-t). Even though other (off-target) effects of 173 
pharmacological GS inhibition cannot be formally excluded, MSO phenocopied the GS 174 
knockdown, suggesting that the catalytic site of GS is indispensable to control EC 175 
cytoskeletal homeostasis. 176 
GS INHIBITION AFFECTS RHOJ ACTIVITY 177 
Small GTPases and their effectors control F-actin levels and motility11, thus we explored if 178 
Rho GTPases were downstream targets of GS. We focused on RHOJ, since it is EC-179 
enriched12, and blocking endothelial RHOJ was proposed to be a novel anti-angiogenesis 180 
approach13. Of note, RHOJKD ECs fully phenocopied GSKD ECs in terms of decreased 181 
mobility and barrier function (data not shown). 182 
Since RHOJ localizes to plasma and organelle membranes to become activated14 and 183 
RHOJ is almost exclusively detected in the membrane fraction15, we explored if GS levels 184 
regulated RHOJs membrane localization and activity. Immunoblotting revealed that RHOJ 185 
was only detectable in the membrane fraction of ECs (consistent with previous findings15), 186 
and that GSKD decreased the amount of RHOJ in the membrane fraction (without 187 
concomitant increase in the cytosolic fraction, possibly because of proteasomal 188 
degradation16) as well as the levels of active RHOJ (Fig. 4b,c). GSKD did not overtly affect 189 
RHOJ transcript levels (relative mRNA levels: 0.99 ± 0.03 in control vs 0.85 ± 0.05 in 190 
GSKD; n=3, P = 0.0282).  191 
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We also explored if GSKD affected other Rho GTPases in ECs. We focused on the 192 
RHOA/B/C  Rho kinase (ROCK)  myosin light chain (MLC) axis, as silencing of 193 
endothelial RHOJ increases signaling of this pathway and induces aberrant F-actin stress 194 
fiber formation through an as yet undefined mechanism13,17 (Fig. 4d). Standard GST-195 
Rhotekin pull-down assays showed that GSKD increased the activity of RHOA and RHOC, 196 
but not of RHOB (Fig. 4e-g). Of note, GSKD, much like other stimuli, increased total RHOB 197 
levels. We confirmed the increase in RHOA activity at the individual cell level with a 198 
DORA-RHOA-FRET biosensor (Fig. 4h; Extended Data Fig. 6a), and observed that the 199 
abnormally elevated RHOA activity in retracting lamellipodia in GSKD ECs evoked more 200 
numerous, but smaller and more short-lived lamellipodia (Fig. 4i), which could contribute to 201 
the motility impairment. As suggested previously18, increased RHOA activity in 202 
lamellipodia locally leads to actomyosin contraction through ROCK and pMLC, thereby 203 
prematurely retracting the lamellipodium. Combining GSKD and RHOJKD did not further 204 
increase RHOA activity (data not shown) confirming that RHOJ silencing by itself 205 
increased RHOA activity and suggesting that GS indeed primarily acts via RHOJ to control 206 
RHOA signaling. 207 
Downstream of Rho GTPases, GSKD and MSO-treated ECs had elevated ROCK1 and 208 
ROCK2 protein levels (Fig. 4j), and enhanced ROCK activity, as determined by pMLC 209 
protein levels, which were similarly induced in GSKD and RHOJKD ECs (Fig. 4k; Extended 210 
Data Fig. 6b-n). In agreement, ROCK inhibitors (Y27632, fasudil hydrochloride and H1152 211 
dihydrochloride (not shown)) rescued the GSKD phenotype (Fig. 4l-o; Extended Data Fig. 212 
6o-w) whereas myosin light chain kinase (MLCK) inhibitors (ML7; peptide 18) did not 213 
(Extended Data Fig. 6x-aa), suggesting that MLC phosphorylation through ROCK rather 214 
than MLCK is more important in mediating the GSKD phenotype in ECs. Thus, GSKD lowers 215 
membrane localization and activity of RHOJ, while activating RHOA, RHOC, and ROCK.  216 
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We explored with which of these Rho GTPases GS interacted, assuming that such an 217 
interaction might facilitate / be necessary for their activation, nonetheless keeping in mind 218 
that RHOJ can negatively regulate the activity of the RHOA/ROCK/MLC axis13,17 and 219 
hence that loss of a primary interaction of GS with RHOJ could indirectly explain the 220 
elevated levels of RHOA/ROCK/MLC upon GSKD. First, co-immunoprecipitation (co-IP) 221 
assays showed interaction between endogenous RHOJ and GS (Fig. 5a). Such co-IP was 222 
not observed for RHOA and RHOC (most abundant in ECs) (Extended Data Fig. 7a). 223 
Second, deletion of the first 20 N-terminal amino acids in RHOJ (ΔN20-RHOJ), mediating 224 
RHOJs plasma membrane localization19, reduced the interaction with GS (Extended data 225 
Fig. 7b). Third, immunoblotting showed that only RHOJ, but not RHOA or RHOC, was 226 
predominantly membrane localized (Extended data Fig. 7c). Fourth, we confirmed the GS-227 
RHOJ interaction with a bimolecular fluorescence complementation approach (BiFC) 228 
(Extended Data Fig. 7d,e). Based on the above data, we focused on RHOJ as most likely 229 
interacting partner of GS.  230 
To interact with membrane-localized (active) RHOJ, GS should be membrane localized as 231 
well. Indeed, cell fractionation studies revealed that a fraction of GS was membrane 232 
localized (Fig. 5b). Further evidence derives from single particle tracking data, acquired by 233 
photoactivated localization microscopy imaging (SPT-PALM), combined with total internal 234 
reflection fluorescence microscopy (TIRF). We traced the movement of single GS proteins 235 
tagged with the photoswitchable fluorescent protein (PSFP) mEOS (GS-mEOS). Single 236 
GS-mEOS particles had a lower diffusion coefficient (DF) in the TIRF region (comprising 237 
the plasma membrane and the immediately adjacent cytoplasm) than free mEOS, 238 
indicative of an association of GS with membrane structures (Fig. 5c; Extended Data Fig. 239 
7f).  240 
PALMITOYLATION OF GS AND RHOJ 241 
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Membrane localization often requires post-translational palmitoylation. We thus 242 
hypothesized that GS could be palmitoylated to allow plasma membrane localization and 243 
interaction with RHOJ. Therefore, we performed click chemistry with biotin-azide 244 
(Extended Data Fig. 7g) on lysates from HEK293 cells overexpressing GS and treated with 245 
the clickable palmitoylation probes 16C-BYA or 16C-YA. Streptavidin pull-down showed 246 
clear palmitoylation of GS, as both probes labeled GS. The labeling was reduced by MSO, 247 
consistent with the presumed dependency of the phenotype on the enzymes catalytic site 248 
(Fig. 5d). 249 
GS was anecdotally reported previously to be palmitoylated, however without further in-250 
depth molecular / functional characterization20. To determine if GS undergoes 251 
autopalmitoylation, we incubated purified GS21 with palmitoyl-alkyne CoA (a substrate for 252 
palmitoylation) in a cell-free system without any other proteins present, to demonstrate a 253 
direct effect. Click chemistry revealed that increasing the dose of palmitoyl-alkyne CoA 254 
resulted in increased autopalmitoylation of GS (Fig. 5e). Importantly, autopalmitoylation of 255 
GS was achieved with physiological concentrations of palmitoyl-CoA (1-10 µM) at neutral 256 
pH, suggesting physiologically relevant autopalmitoylation and was confirmed with two 257 
alternative methods (Supplementary Discussion 2 and Extended Data Fig. 7h-j).  258 
Palmitoylation of target proteins by palmitoyl-acyl transferases (PATs) is a two-step 259 
reaction, requiring first autopalmitoylation of the PAT, and thereafter, transfer of the 260 
palmitoyl group to the target protein. We hypothesized GS to have a similar activity profile 261 
(Supplementary Discussion 3) and explored if GS was involved in palmitoylation of RHOJ. 262 
Even though RHOJs cysteines at position 3 (C3) and 11 (C11) were in silico predicted to 263 
be high fidelity palmitoylation sites (screened with SwissPalm22, data not shown), 264 
palmitoylation of RHOJ has been poorly documented (except in a few studies23,24). 265 
Interestingly, RHOJs membrane localization and activity were reduced by treatment of 266 
ECs with the pan-palmitoylation inhibitor 2-bromopalmitate (2BP) and by point mutating 267 
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cysteines C3 and C11 (Fig. 5f; Extended Data Fig. 7k-t), providing initial evidence that 268 
RHOJ can be palmitoylated in ECs. Using the palmitoylation probe 17-ODYA (Fig. 5g) or 269 
an acyl-resin-assisted capture (acyl-RAC; Extended Data Fig. 7u), we found a reduction in 270 
the levels of palmitoylated RHOJ upon blocking GS, consistent with a model whereby GS 271 
sustains palmitoylation of RHOJ.  272 
 273 
DISCUSSION 274 
Surprisingly, we found a glutamine synthesizing-independent activity for GS in regulating 275 
EC motility, even though we cannot formally exclude a possible contribution of minimal 276 
levels of glutamine production by GS to the observed phenotype. Indeed, GS regulates 277 
RHOJ signaling in cell motility as shown by several lines of evidence. First, a fraction of 278 
GS is present in EC membranes, where active RHOJ resides. Second, GS interacts with 279 
RHOJ in ECs in co-IP experiments (though this interaction can be direct / indirect). Third, 280 
GSKD reduces RHOJs palmitoylation, membrane localization and activity in ECs. Thus, 281 
since RHOJ promotes EC motility13,17, the impaired migration of GSKD ECs could be 282 
attributed to the reduced RHOJ activity. RHOJ likely also indirectly contributes to 283 
promoting EC motility through controlling the activity of the RHOA/ROCK/MLC signaling 284 
pathway, known to regulate EC motility by affecting stress fiber formation13,17 (Extended 285 
Data Fig. 7v; Supplementary Discussion 4).  286 
Because purified GS seems capable of autopalmitoylation (a trademark of PAT enzymes), 287 
and GS silencing lowers RHOJ palmitoylation, our data support a model, whereby GS first 288 
autopalmitoylates itself and thereafter transfers the palmitoyl group to RHOJ, though we 289 
cannot formally exclude that transfer of the palmitoyl group from GS to RHOJ occurs via 290 
additional partners or even non-enzymatically. A possible model for GS palmitoylation is 291 
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described in Supplementary Discussion 5, Extended Data Fig. 8 and Extended Data Table 292 
2. Also, whether the GS-RHOJ partnership is exclusive or GS interacts with other players 293 
(eg other palmitoylated RhoGTPases such as RAC1, CDC42, RHOU or RHOV) to mediate 294 
this effect on EC motility, remains outstanding. In any case, RHOJ seems to be a critical 295 
target of GS, given that its silencing completely phenocopies GS inhibition in ECs. 296 
Finally, GS is critical for EC motility / migration, contributing to the formation of new 297 
vessels in development and disease. In contrast, ECs do not migrate when they are 298 
quiescent in healthy adults, explaining why GS inhibition has no observable effects on the 299 
vasculature in healthy adult mice. This renders GS an attractive disease-restricted target 300 
for therapeutic inhibition of pathological angiogenesis. In agreement, the pharmacological 301 
GS blocker MSO reduced pathological angiogenesis in blinding eye and psoriatic skin 302 
disease (Fig. 2), which warrants further exploration of GS targeting in anti-angiogenesis.  303 
 304 
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LEGENDS TO FIGURES  440 
FIGURE 1: EC-SPECIFIC DELETION OF GS CAUSES VASCULAR DEFECTS IN VIVO 441 
a, GS expression (arrowheads) in the retinal microvasculature (co-stained with isolectin B4 442 
(IB4)) of five day-old (P5) chimeric GS+/GFP pups (with zoom-in inset). b, GS protein levels 443 
in HUVECs under different extracellular glutamine levels. c, GS mRNA levels upon 444 
activation of VE-cadherin-CreERT2. d-g, IB4 staining of P5 retinal vascular plexi from WT 445 
(d) and GSvECKO (e) mice (with zoom-in insets, A=artery, V=vein) and quantification of 446 
branch points at the front of the plexus (f) and radial expansion of the plexus (g). h, Vessel 447 
regression (area of collagen IV (Col IV)+ IB4- vessel sleeves (% of total Col IV+ area)) in 448 
retinas from P5 WT and GSvECKO pups. i-j, Distal sprouts (i) and filopodia (j) at the retinal 449 
vascular front. k-m, IB4 (gray)/EdU (cyan) double staining of P5 WT (l) and GSvECKO (m) 450 
retinas (arrowheads in zoom-in insets denote EdU+ ECs) and quantification (k) of EdU+ 451 
ECs at the front of the plexus. n-r, CD31-stained dermal dorsal blood vasculature in E16.5 452 
WT (n,o) and GSvECKO (p,q) mice with boxed regions magnified in (o) and (q) and 453 
quantification of number of branch points (r). All data are mean±s.e.m; n-number 454 
(individual experiments) is 2 (a,b); n-numbers (individual mice) for WT and GSvECKO are: 3 455 
and 3 (c); 11 and 10 (f); 10 and 7 (g); 4 and 6 (h); 18 and 22 (i); 17 and 21 (j); 12 and 22 456 
(k); 5 and 15 (r), from 2 (g,h,r), 3 (f) or 4 (i,j,k) litters. NSP>0.05, *P<0.05 according to 457 
Students t test (c,g,h,i,j,k,r) or mixed models R statistics (f). Exact P values: (c) 0.0215; (f) 458 
0.0141; (g) 0.0063; (h) 0.4902; (i) 0.0009; (j) 0.0484; (k) 0.3837; (r) 0.0046. Scale bars: 10 459 
µm (a right), 50 µm (a left), 100 µm (l,m), 200 µm (d,e,n,p). Gel source images: see 460 
Supplemental Information Fig. 1. 461 
 462 
 463 
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 464 
FIGURE 2: GS INHIBITION MITIGATES PATHOLOGICAL ANGIOGENESIS 465 
a-d, Retinal flat-mounts of retinopathy of prematurity (ROP) mice treated with vehicle (a) or 466 
20 mg kg-1 d-1 MSO (b). Quantification of vascular tuft (c) and vaso-obliterated area (d) in 467 
control and MSO-treated ROP pups. e-g, Quantification (e) of CD31+ (green) neo-vessels 468 
in corneal flat-mounts from mice in corneal pocket assays (CPA) with bFGF pellets 469 
(demarcated by dotted white line) with vehicle (f) or MSO (g). h-l, CD105 staining of 470 
untreated skin (h), IMQ-treated skin (i), IMQ + low dose MSO-treated skin (j), IMQ + high 471 
dose MSO-treated skin (k), and quantification of CD105+ area (l). All data are 472 
mean±s.e.m.; n-numbers (individual mice) for control and MSO-treated are: 7 and 6 (c,d), 473 
10 and 11 (e) from 3 litters (c,d) and 2 experiments (e). In (l) n=15 for control, n=22 for 474 
IMQ, n=18 for IMQ + MSO low (indicated by +) and n=6 animals for IMQ + MSO high 475 
(indicated by ++) from 3 experiments. NSP>0.05, *P<0.05 according to Students t test 476 
(c,d,e) or ANOVA with Dunnetts multiple comparisons vs IMQ (l). Exact P values (c) 477 
0.0459; (d) 0.0145; (e) <0.0001; (l) ctrl vs IMQ: 0.0278; MSO low vs IMQ: 0.7283; MSO 478 
high vs IMQ: 0.0451. bFGF: basic fibroblast growth factor; CD31: cluster of differentiation 479 
31; IMQ: imiquimod; MSO: methionine sulfoximine. Scale bars: 100 µm (a,b), 200 µm (f,g), 480 
75 µm (h-k). 481 
 482 
FIGURE 3: LOSS OF GS IMPAIRS EC MIGRATION THROUGH PERTURBED ACTIN DYNAMICS 483 
a-f, Control (a,c) and GSKD (b,d) EC spheroids without (a,b) and with mitomycin C (MitoC) 484 
(c,d) treatment and number of sprouts per spheroid (e) and total sprout length (f). g, [3H]-485 
Thymidine incorporation in control and GSKD ECs. h, Wound closure upon MitoC-treatment 486 
of control and GSKD ECs. i, Boyden chamber migration for control, GSKD and GSKD + 487 
rGSOE (overexpression of a shRNA-resistant GS mutant) ECs, all under MitoC-treatment. 488 
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j, Velocity of sparsely seeded control and GSKD ECs. k-m, Phalloidin (F-actin) staining of 489 
control (k) and GSKD (l) ECs (arrows and white dotted lines indicate lamellipodia) and 490 
quantification of lamellipodial area (m). n-p, F-actin and G-actin levels in phalloidin (F-491 
actin)  DNAse I (G-actin) double-stained control and GSKD ECs (n), and representative 492 
images of phalloidin-stained control (o) and GSKD (p) ECs. q-u, Phalloidin staining of 493 
latrunculin B-treated control (q,s) and GSKD (r,t) ECs at timepoint 0 (q,r) and at 1 h after 494 
latrunculin wash-out (s,t) and quantification of F-actin levels after wash-out (u). v, α-495 
Tubulin levels in GSKD and control ECs. All data are mean±s.e.m.; n-numbers 496 
(independent experiments) are: 4 (e,f), 9 (g,j), 5 (h), 6 (i,u), 7 (m) and 3 (n,v). NSP>0.05, 497 
*P<0.05 according to mixed models R statistics (e,f), Students t test (g,h,j,m,n,u,v) or 498 
ANOVA with Dunnetts multiple comparison vs control (i). Exact P values (e,f) ctrl vs GSKD 499 
± mitoC: <0.0001; (g) 0.7729; (h) 0.0283; (i) ctrl vs GSKD: 0.0093; ctrl vs GSKD + rGSOE: 500 
0.5981; (j) 0.0234; (m) 0.0352; (n) F-actin: 0.0467; G-actin: 0.584; (u) 0.0007; (v) 0.3491. 501 
AU, arbitrary units. Scale bars: 100 µm (a-d), 10 µm (k,l) and 20 µm (o-t). 502 
 503 
FIGURE 4: ENDOTHELIAL GS REGULATES RHOGTPASE ACTIVITY  504 
a, Effect of glutamine and MSO on glutamine-producing activity (% enrichment in m+1 505 
glutamine and glutamate, 30 min after adding 15NH4
+). b, RHOJ, NaK ATPase (membrane 506 
marker) and GAPDH (cytosol marker) immunoblots in cytosolic (c) and membrane (m) 507 
fractions with quantification c, Immunoblot for active and total RHOJ with quantification 508 
(RHOJKD, beads only and irrelevant biotinylated peptide are negative controls) d, RHOJs 509 
pivotal yet incompletely understood (question mark) role in EC migration/stress fiber 510 
formation. e-g, Immunoblots for pull-down RHOA (e), RHOB (f) and RHOC (g) activity 511 
assays with quantifications. h, Control and GSKD ECs expressing the DORA RHOA 512 
biosensor, with quantification of whole-cell FRET startratio (mean±s.e.m.; control, n=12 513 
cells; GSKD, n=9). Look-up table (LUT; color bar) denotes relative RHOA activities 514 
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(blue=low, red=high). i, Kymograph of DORA RHOA biosensor expressing ECs, showing 515 
abnormally short-lived lamellipodia and increased RHOA activity in retracting lamellipodia 516 
of GSKD ECs (red arrowheads) (representative of 13 control and GSKD cells). j, ROCK1, 517 
ROCK2, α-tubulin immunoblots with quantification. k, pMLC, total MLC and α-tubulin 518 
immunoblots (quantification see Methods section). l, F-actin levels after latrunculin B 519 
wash-out in ECs treated with the ROCK inhibitor Y27632. m-o, Effect of Y27632 on 520 
spheroid sprouting defect (m), migration defect (n), and lamellipodial area (o). Values in 521 
l,n,o are relative to untreated non-silenced control (dotted line). pMLC: phosphorylated 522 
MLC. Scale bar is 25 µm (h). All data are mean±s.e.m.; n-numbers (independent 523 
experiments) are: 3 (a,e,f,m,n), 4 (c(MSO),h,k,l), 5 (o), 7 (j), 8 (c(GSKD), g), 13 (b). 524 
NSP>0.05, #P=0.05, *P<0.05; ANOVA with Dunnetts multiple comparisons vs 4 mM (a), 525 
one sample t test (b,c,e,f,g,j,k), Students t test (h,n,o), paired Students t test (l) or mixed 526 
models R statistics (m). Exact P values (a) (Glu) 0.6 mM vs 4 mM: 0.9903; 0.025 mM + 527 
MSO vs 4 mM: 0.0968; 0.025 mM vs 4 mM: 0.1943; (Gln) 0.6 mM vs 4 mM: 0.4518; 0.025 528 
mM + MSO vs 4 mM: 0.9999; 0.025 mM vs 4 mM: 0.0143; (b) 0.0072; (c) MSO: 0.0323; 529 
GSKD: 0.0095; (e) 0.053; (f) 0.1790; (g) 0.0035; (h) 0.0055; (j) ROCK1 MSO: 0.0169; 530 
ROCK1 GSKD: 0.0138; ROCK2 MSO: 0.0381; ROCK2 GSKD: 0.0802; (k) MSO: 0.0283; 531 
GSKD: 0.0431; RHOJKD: 0.0091; (l) 0.0431; (m) GSKD vs ctrl: <0.0001; GSKD + Y27632 vs 532 
ctrl + Y27632: 0.5211; (n) 0.0181; (o) 0.0210. Gel source images: see Supplemental 533 
Information Fig. 1. 534 
 535 
FIGURE 5: GS (AUTO)-PALMITOYLATION 536 
a, Co-immunoprecipitation (Co-IP) of endogenous RHOJ and GS in ECs. Upper panel: IP 537 
of RHOJ; lower panel: IP for GS. b, Immunoblot for GS and RHOJ in cytosolic (c) and 538 
membrane (m) fractions in ECs with NaK and GAPDH as fraction markers. c, Diffusion 539 
coefficient (DF, in µm2 s-1) of single photoswitchable fluorescent protein mEOS and mEOS-540 
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fused GS (mEOS-GS) particles in the plasma membrane region of ECs acquired by SPT-541 
PALM under TIRF illumination (n=41 cells expressing mEOS and 37 expressing mEOS-542 
GS) d, GS immunoblotting after streptavidin pull-down of biotin-azide clicked lysates from 543 
HEK-293T cells for the indicated palmitoylation probes. Input shows levels of GS 544 
overexpression. e, Dose-effect of palmitoyl-alkyne CoA on autopalmitoylation of purified 545 
GS; biotin-azide clicking and HRP-streptavidin blotting; input on Coomassie-stained gel. f, 546 
Immunoblotting for RHOJ, NaK and GAPDH in membrane (m) and cytosolic (c) fractions of 547 
control- and 2BP-treated ECs. g, Palmitoylation of RHOJ in GSKD, MSO- and 2BP-treated 548 
ECs. In-gel fluorescence for TAMRA-azide 17-ODYA (palmitoylation probe)-clicked FLAG-549 
RHOJ is shown (FLAG as loading control). 2BP, 2-bromopalmitate, pan-palmitoylation 550 
inhibitor. All data are mean±s.e.m., except box and whisker (running from minimal to 551 
maximal values) plots in (c); n-numbers (independent experiments) are: 2 (e), 3 (a,b,c,d,f), 552 
4(g). NSP>0.05, *P<0.05; Students t test (c); one sample t test (f,g). Exact P values (c) 553 
<0.0001; (f) 0.0264; (g) MSO: 0.0317; GSKD: 0.0003; 2BP: 0.0163. Gel source images: see 554 
Supplemental Information Fig. 1. 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
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 566 
 567 
 568 
METHODS 569 
CHEMICALS AND REAGENTS: The GS inhibitor L-methionine sulfoximine (MSO), mitomycin C, 570 
latrunculin B, oligomycin, antimycin A, carbonyl cyanide-4-(trifluoromethoxy) 571 
phenylhydrazone (FCCP), 2-bromohexadecanoic acid (2-bromopalmitic acid, 2BP), 572 
tamoxifen, palmitoyl-CoA agarose and α-ketoglutarate dehydrogenase were from Sigma-573 
Aldrich. 17-Octadecynoic acid (17-ODYA) was purchased from Cayman Chemical. The 574 
use and/or synthesis of the other palmitoylation probes 15-hexadecynoic acid (16C-YA; a 575 
palmitate-based probe that binds a broader spectrum of proteins than 16C-BYA (here 576 
below), including both PATs and PAT target proteins) and 2-bromooctadec-15-yonic acid 577 
(16C-BYA; a 2-bromopalmitate-based activity-based probe that labels but also inhibits 578 
palmitoyl acyltransferase (PAT) enzymes) has been described previously25. The ROCK 579 
kinase inhibitor Y27632 ((1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-580 
yl)cyclohexanecarboxamide) was from BioVision, fasudil hydrochloride and H1152 581 
dihydrochloride are from Tocris. The MLCK inhibitors ML7-hydrochloride and peptide 18 582 
were from Tocris. Collagen type 1 (rat tail) was obtained from Merck Millipore. [5-3H]-583 
glucose, [3H]-thymidine, [U-14C]-glutamine were from Perkin Elmer; [6-14C]-D-glucose was 584 
from ARC. [U-13C]-glucose, [U-13C]-glutamine, [U-13C]-glutamate and 15NH4Cl
 were 585 
purchased from Cambridge Isotope Laboratories. The following primary antibodies or dyes 586 
were used (dilutions for staining (ST), immunoblotting (IB), immunofluorescence (IF) and 587 
immunoprecipitation (IP) are given in between brackets): Griffonia simplicifolia (GS)-IB4-588 
Alexa 488 (ST 1:200), isolectin GS-IB4-Alexa 568 (ST 1:200), isolectin GS-IB4-Alexa 647 589 
(ST 1:200), phalloidin-Alexa 488 (ST 1:100), deoxyribonuclease I-Alexa 594 (ST 1:200) 590 
(Molecular Probes), anti-collagen IV (2150-1470) (IF 1:400) (Bio Rad), anti-NG2 591 
7/18/2018 24
Chondroitin Sulfate Proteoglycan (AB5320) (IF 1:200) (Millipore), anti-FLAG (clone M2) (IB 592 
1:1,000; IP 5 µg ml-1), anti-GS (clone 2B12) (IB 1:1,000; IP 2-5 µg ml-1), anti-RHOJ (clone 593 
1E4) (IB 1:1,000; IP 2-5 µg ml-1), anti-ROCK1 (HPA007567) (IB 1:1,000), anti-α-tubulin 594 
(T6199) (IB 1:1,000) (Sigma-Aldrich), anti-ȕ-actin (13E5) (IB 1:1,000), anti-phospho-595 
Myosin Light Chain 2 (IB 1:1,000; IF 1:300) and anti-Myosin Light Chain 2 (IB 1:1,000) 596 
(9776), anti-Na,K-ATPase (NaK) (3010) (IB 1:1,000), anti-RHOA (67B9) (IB 1:1,000) and 597 
anti-RHOC (D40E4) (IB 1:1,000) (Cell Signaling Technology), anti-CD105/endoglin 598 
(AF1320) (IF 1:50), anti-VE-cadherin (AF1002) (IF 1:50) (R&D Systems), anti-ROCK2 599 
(A300-047A-T) (IB 1:500) (Imtec Diagnostics), anti-CD31 (MEC13.3) (IF 1:200), anti-600 
CD34-biotin (#553732) (IF 1:25) (BD Biosciences), anti-RHOB (sc-180) (IB 1:1,000). 601 
Secondary Alexa-405, -488, -568 or -647 conjugated antibodies (1:500) were from 602 
Molecular Probes; other secondary antibodies and IgG controls were from Dako. The 603 
Click-iT® 5-ethynyl-2´-deoxyuridine (EdU) Alexa Fluor® 555 Imaging Kit was from 604 
Invitrogen. Purified bacterial GS was a kind gift from Rod Levine (Bethesda, MD, USA).  605 
CELL CULTURE: HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVECS) AND HUMAN UMBILICAL 606 
ARTERY ENDOTHELIAL CELLS (HUAECS) obtained under protocol S57123 (Commission 607 
Medical Ethics of UZ/KU Leuven) after written consent of the donors, were isolated as 608 
previously described 1,2 and were routinely cultured in M199 medium (Invitrogen) 609 
containing 20% FBS, 0.6 mM L-glutamine, heparin (10 U ml-1; Sigma), penicillin (100 U ml-610 
1), streptomycin (100 µg ml-1) and endothelial cell growth factor supplements (EGCS; 30 611 
mg l-1; Sigma). Cells were only used between passages 1 and 4 and all experiments were 612 
performed in HUVECs from at least three different donors unless stated otherwise. Also 613 
except when stated otherwise, the use of the abbreviation EC in the text refers to HUVEC. 614 
ISOLATION OF ENDOTHELIAL CELLS FROM HUMAN LUNG/LIVER/COLON MUCOSA: Lung/liver/colon 615 
mucosa specimens were obtained under protocol S57123 (Commission Medical Ethics of 616 
UZ/KU Leuven) and were washed several times with phosphate buffer solution (PBS) and 617 
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minced with scissors prior to enzymatic digestion for 45 min. at 37 °C with 618 
collagenase/dispase/DNase solution (Gibco, Life Technologies). The resulting suspension 619 
was passed through a 100 ߤm nylon mesh (BD Biosciences Pharmingen) to remove 620 
aggregates. The harvested cells were washed, seeded on gelatin pre-coated 6-well plates 621 
and cultured in complete endothelial growth medium (EGM-MV; Lonza) supplemented with 622 
antibiotics. After 5-7 days, when cells reached confluency, a positive CD31 magnetic bead 623 
selection was performed (CD31 MicroBead, #130-091-935, Miltenyi Biotech) according to 624 
the manufacturers guidelines and purified cells were further cultured in EGM medium. 625 
PERIPHERAL BLOOD OUTGROWTH ENDOTHELIAL CELLS (BOECS) were established and cultured 626 
as previously described 26. In brief, blood samples (obtained under protocol S57123 627 
(Commission Medical Ethics of UZ/KU Leuven) were diluted with PBS prior to Ficoll 628 
PaquePLUS (GE Healthcare) density-gradient centrifugation at 1,000 g for 20 min at room 629 
temperature. The mono-nuclear cell layer was collected, washed with PBS and 630 
resuspended in EGM2 medium (PromoCell). Cells were plated in collagen-coated flasks 631 
and medium was replaced every 2 days. From day 7 onwards, cells were checked for the 632 
formation of colonies, which were allowed to grow up to approximately 1 cm2. BOEC 633 
colonies were then trypsinized and subcultured. HEK293T AND HEPG2 CELLS (ATCC) were 634 
grown in DMEM, supplemented with 10% fetal bovine serum (FBS), 100 U ml-1 penicillin 635 
and 100 ȝg ml-1 streptomycin. When HEPG2 cells were compared directly to ECs in short 636 
term stable isotope tracing experiments, they were incubated in exactly the same medium 637 
as the ECs to rule out possible bias coming from the difference in media formulation. We 638 
did not perform authentication of the HEK293T and HEPG2 cells. MOUSE LIVER 639 
ENDOTHELIAL CELLS (MLIECS) were isolated from perfused healthy livers of control or 640 
GSECKO mice. Prior to perfusion, the mice were anesthetized with Nembutal (60 mg kg-1). 641 
Mice were perfused with 5 ml of a water-based perfusion buffer containing 1.7 M NaCl, 84 642 
mM KCl, 120 mM HEPES and 1 mM NaOH followed by 5 ml of a PBS-based digestion 643 
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buffer containing 0.1% collagenase II (Life Technologies), collagenase I (Life 644 
Technologies), 2 mM CaCl2, 1% antibiotic-antimycotic (Life Technologies) and 10% FBS 645 
(Biochrome, Berlin, Germany) at a perfusion rate of 1 ml min-1. Perfusion was considered 646 
complete when the liver and mesenteric vessels were blanched and the desired amount of 647 
digestion buffer ( 5ml) had passed through the circulatory system. Livers were dissected, 648 
placed into a 50 ml conical tube with 3 ml of digestion buffer and incubated at 37 °C for 649 
approximately 30 min, with regular shaking of the tubes every 5 min. After digestion, the 650 
tissue was homogeneously dissociated and the reaction was stopped with 10 ml of 651 
isolation buffer containing PBS + 0.1% BSA (Sigma-Aldrich). Subsequently, the cell 652 
suspension was filtered through a 100 ȝm cell strainer and cells were washed twice with 653 
isolation buffer. Finally, the ECs were isolated by magnetic bead sorting with Dynabeads 654 
(CELLectionTM Biotin Binder Kit, Life Technologies, Ghent, Belgium) coated with anti-655 
mouse CD31 (eBioscience, Anti-Mouse CD31 Clone 390), according to the manufacturers 656 
instructions. Briefly, the cell suspension was incubated with the beads at room 657 
temperature for 30 min in HulaMixer® Sample Mixer (Life Technologies, Ghent, Belgium). 658 
Next, CD31+ ECs were collected by putting the tubes on a DynaMagTM-50 Magnet (Life 659 
Technologies) and removing the supernatant. The procedure was repeated twice to 660 
remove cells debris. Finally, cells were resuspended in EGM2 medium (PromoCell) and 661 
plated at the desired density on cell culture plates pre-coated with 0.1% gelatin, and grown 662 
to confluency. MOUSE ASTROCYTES were prepared as described previously with minor 663 
changes 27. Briefly, spinal cords were dissected from 13-day old C57BL/6J mouse 664 
embryos. Meninges and dorsal root ganglia were removed and a single cell population 665 
was obtained by digestion with 0.05% trypsin in combination with gentle trituration. The 666 
cell suspension was layered on a 6.2% OptiPrep (Axis-Shield, Oslo, Norway) cushion 667 
and centrifuged at 500g for 15 min. The pellet was resuspended and the cells were plated 668 
(12,000 cells cm-2) in L15 medium supplemented with glucose (3.6 mg ml-1), sodium 669 
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bicarbonate (0.2%), penicillin (100 IU ml-1), streptomycin (100 µg ml-1) and fetal bovine 670 
serum (10%). After reaching confluency, cell division was halted by treatment with cytosine 671 
arabinoside (10 µM, 3 days). After 4 weeks, more than 95% of cells stained positive for 672 
glial fibrillary acidic protein (GFAP; not shown). We routinely tested primary cells and cell 673 
lines for mycoplasma contamination with the MycoAlert mycoplasma detection kit (Lonza, 674 
LT07-418). 675 
PLASMID CONSTRUCTIONS AND LENTIVIRAL PARTICLE PRODUCTION: cDNA for human GS was 676 
obtained from Origene. Silent mutations were introduced to make the GS cDNA resistant 677 
to the GS-specific shRNA (see below, TRCN0000045628). Point-mutated constructs were 678 
generated with Stratagenes QuickChange site-directed mutagenesis kit following 679 
manufacturers guidelines. The cDNA for RHOJ-EGFP (GFP-TCL) was a gift from 680 
Channing Der (Addgene plasmid # 23231) 23 and was used as a template to generate the 681 
N-terminal truncated ΔN20-RHOJ-EGFP, lacking the first 20 amino acids and FLAG-682 
tagged RHOJ. Standard cloning techniques were used to fuse GS to the photoswitchable 683 
fluorescent protein mEOS (pRSETa-mEos2 was a gift from Loren Looger; Addgene 684 
plasmid # 20341)28. The BiFC vector allowing simultaneous expression of two separate 685 
cDNAs fused to EGFP subfragment 1 (N-terminal; containing amino acids 1 to 158) or 686 
subfragment 2 (C-terminal; containing amino acids from 159 onwards) respectively was a 687 
kind gift of Prof. Hideaki Mizuno (KU Leuven). GS was fused to the N-terminal 688 
subfragment of EGFP and RHOJ was fused to the C-terminal EGFP subfragment to 689 
generate GS-EGFP1/2, RHOJ-EGFP2/2. Lentiviral expression constructs were obtained by 690 
cloning the respective cDNAs into pRRLsinPPT.CMV.MCS MM WPRE-vector. Validated 691 
GS-specific (TRC clones TRCN0000045628 (used in the majority of the experiments and 692 
indicated as GSKD1 in Extended Data Fig. 2a) and TRCN0000045631 (indicated as GSKD2 693 
in Extended Data Fig. 2a and only used to confirm the migration and lamellipodial defect in 694 
Extended Data Fig. 3a-b) and RHOJ-specific (TRCN0000047606) shRNAs were either 695 
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used in the pLKO.1 vector  or subcloned into the pLVX-shRNA2 vector (No. PT4052-5; 696 
Clontech, Westburg BV, Leusden, the Netherlands). Scrambled shRNAs or the empty 697 
vectors were used as negative controls (both with the same outcome). All constructs were 698 
sequence verified. Lentiviral particles were produced in HEK293T cells as previously 699 
described 2. 700 
RECOMBINANT PROTEIN PRODUCTION: Template vectors pRRLhGS, pRRLhGSR324C and 701 
pRRLhGSR341C containing the gene encoding wild type or point mutated human GS were 702 
used as templates for PCR-based cloning. Recombinant constructs were expressed in the 703 
Escherichia coli strain BL21 codon + pICA2 that was transformed with pLH36-hGS in 704 
which expression is induced by isopropyl b-D-1-thiogalactopyranoside under control of a 705 
pL-promotor developed by the Protein Core of VIB (WO 98/48025, WO 04/074488). The 706 
pLH36 plasmid is provided with a His6-tag followed by a murine caspase-3 site. The 707 
murine caspase-3 site can be used for the removal of the His6-tag attached at the N-708 
terminus of the protein of interest during purification. The transformed bacteria were grown 709 
in 200 ml Luria Bertani medium supplemented with ampicillin (100 µg ml-1) and kanamycin 710 
(50 µg ml-1) overnight at 28 °C before 1/100 inoculation in a 20 l fermenter provided with 711 
Luria Bertani medium supplemented with ampicillin (100 µg ml-1) and 1 % glycerol. The 712 
initial stirring and airflow was 200 rpm and 1.5 l min-1, respectively. Further, this was 713 
automatically adapted to keep the pO2 at 30 %. The temperature was kept at 28 °C. The 714 
cells were grown to an optical density of A600nm = 1.0, transferred at 20 °C, and expression 715 
was induced by addition of 1 mM isopropyl b-D-1-thiogalactopyranoside overnight. Cells 716 
were then harvested and frozen at -20 °C. After thawing, the cells were resuspended at 3 717 
ml g-1 in 50 mM Hepes pH 7.5, 500 mM NaCl, 20mM imidazole, 1 mM phenyl-718 
methylsulfonyl fluoride, 10 % glycerol, 5 mM ȕ-mercaptoethanol, 1 mg per 100 ml DNAseI 719 
(Roche) and 1 tablet per 100 ml Complete Protease Inhibitor (Roche). The cytoplasmic 720 
fraction was prepared by using the Emulsiflex followed by centrifugation. All steps were 721 
7/18/2018 29
conducted at 4 °C. The clear supernatant was applied to a 20 ml Ni-Sepharose 6 FF 722 
column (GE Healthcare), equilibrated with 50 mM Hepes pH7.5, 500 mM NaCl, 20mM 723 
imidazole, 10 % glycerol, 5 mM ȕ-mercaptoethanol and 1 mM phenyl-methylsulfonyl 724 
fluoride. The column was eluted with 50 mM Hepes pH 7.5, 500 mM NaCl, 400 mM 725 
imidazole, 10 % glycerol, 5 mM ȕ-mercaptoethanol and 1 mM phenyl-methylsulfonyl 726 
fluoride after an intermediate elution step with 50 mM imidazole in the same buffer. Finally, 727 
the elution fraction was injected on a HiLoad 26/60 Superdex prep grade with 20 mM 728 
Hepes pH 7.5, 300 mM NaCL, 10 % glycerol and 0.5 mM TCEP as running solution. The 729 
obtained elution fractions were analyzed by SDS-PAGE. Recombinant protein 730 
concentration was determined using the Micro-BCA assay (Pierce). 731 
IN VITRO KNOCK-DOWN/OVEREXPRESSION STRATEGIES: To minimize off-target effects and 732 
other silencing artifacts, key findings were confirmed with at least two independent and 733 
validated GS-specific shRNAs (see above) and appropriate controls or with a GS-specific 734 
siRNA duplex (5-GGAAUAGCAUGUCACUAAAGCAGGC-3) and scrambled control 735 
(TriFECTaTM, IDT). For lentiviral transduction of shRNAs or overexpressing constructs an 736 
MOI of 10 or 5 was used, respectively. In case of simultaneous transduction of 2 different 737 
shRNAs, a MOI 7.5 was used for each individual shRNA. In case of simultaneous 738 
transduction of a shRNA in combination with an overexpression construct, the shRNA was 739 
transduced at MOI 10 and the overexpression construct at MOI 5, except for 740 
overexpression constructs for shRNA-resistant GS which were transduced at MOI 2.5. 741 
Transductions were performed on day 0 in the evening, cells were refed with fresh medium 742 
on day 1 in the morning and experiments were performed from day 3 or 4 onwards. siRNA 743 
transfection mixtures (in a total volume of 500 µl) were prepared in Opti-MEM containing 744 
GlutaMAX-I (Invitrogen) with Lipofectamine RNAi Max transfection reagent (Invitrogen, 745 
Belgium) according to the manufacturers instructions. The mixtures were added to the 746 
cells (150,000 cells in 6 well-format plate) together with 2 ml EBM2 without antibiotics for 747 
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overnight transfection after which the medium was changed back to the regular M199 748 
culture medium. siRNA transfection was done at least 48 h prior to functional assays. BiFC 749 
plasmids were transfected into HEK293T cells with Fugene® HD transfection reagent 750 
following the manufacturers guidelines. KD efficiency and overexpression levels were 751 
closely monitored for each experiment either on mRNA (QRT-PCR) or protein level.  752 
RNA ISOLATION AND GENE EXPRESSION ANALYSIS: Total RNA was extracted with Invitrogens 753 
PureLink RNA mini kit according to the manufacturers instructions; quality and quantity 754 
were measured on a Nanodrop (Thermo Scientific). cDNA synthesis was performed with 755 
the iScript cDNA synthesis kit (BioRad). Quantitative RT-PCR analyses were performed as 756 
previously described 1 on an Applied Biosystems 7500 Fast device with in house-designed 757 
primers and probes or premade primer sets (Applied Biosystems or Integrated DNA 758 
Technologies) for which sequences and/or primer set ID numbers are available upon 759 
request. ENOX2 or HPRT were used as housekeeping genes.  760 
WESTERN BLOTTING AND (CO-)IMMUNOPRECIPITATION: Proteins were extracted in Laemmli 761 
buffer (125 mM Tris-HCl (pH 6.8), 2% SDS,10% glycerol) or in RIPA buffer (25 mM Tris-762 
HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing 763 
protease and phosphatase inhibitor mixes (Roche Applied Science). After shearing of 764 
genomic DNA, proteins in the lysates were separated by SDS-PAGE, transferred to 765 
nitrocellulose or polyvinylidene difluoride membranes and detected with specific antibodies 766 
and HRP-conjugated secondary antibodies in combination with ECL or SuperSignal Femto 767 
Western blotting substrate (Thermo Scientific). Signal was acquired with Image Quant LAS 768 
4000 V 1.2 and densitometric quantification was done with ImageJ. For MLC and pMLC 769 
immunoblotting, each sample was loaded on two separate gels. One gel was used to 770 
detect MLC and the second was used to detect pMLC. Both gels had their own loading 771 
control, namely α-tubulin. pMLC/MLC was quantified as follows: (pMLC/α-tubulin)/(MLC/α-772 
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tubulin), abbreviated in the figure panel as (c)pMLC/(c)MLC with (c) meaning corrected for 773 
corresponding loading control. Membrane versus cytosolic protein fractions were purified 774 
with the Plasma Membrane Protein Extraction Kit (101Bio) according to the manufacturers 775 
guidelines and using proprietary buffers. For co-immunoprecipitation (co-IP) of 776 
endogenous or overexpressed proteins, ECs were lysed by rotating at 4 °C during at least 777 
4 h in co-IP lysis buffer (20 mM Tris-HCl pH8, 137 mM NaCl, 10% glycerol, 1% nonidet 778 
NP-40 and 2 mM EDTA). Equal amounts of protein were incubated overnight with specific 779 
antibodies or matching isotype control IgGs at 4 °C. Subsequently, 20 ȝl of protein A/G-780 
Sepharose beads was added to the immune complexes for 4 h at 4 °C under gentle 781 
rotation. The beads were pelleted, washed three times with ice-cold co-IP lysis buffer and 782 
boiled for 5 min in reducing agent and loading buffer prior to SDS-PAGE. To determine the 783 
impact of deleting RHOJs first 20 N-terminal AAs on the interaction with GS, co-IPs were 784 
done as above on ECs simultaneously overexpressing GS and RHOJ-EGFP or ΔN20-785 
RHOJ-EGFP. In some of the experiments the expression of the ΔN20-RHOJ-EGFP was 786 
lower than the expression of RHOJ-EGFP. To correct for this possible bias, densitometric 787 
quantification of all bands was performed in ImageJ and signals in the IP lanes were 788 
normalized to the input signals. The amount of GS IPed was the same in the RHOJ-EGFP 789 
and ΔN20-RHOJ-EGFP condition (data not shown). 790 
BIOCHEMICAL AND METABOLIC ASSAYS: BICINCHONINIC ACID (BCA) ASSAY (Pierce) was used to 791 
determine protein content with Gen5 1.11.5 (BioTek Instruments). LDH RELEASE as a 792 
measure for cell survival was determined with the Cytotoxicity Detection Kit (Roche 793 
Applied Science) with Gen5 1.11.5 (BioTek Instruments). INTRACELLULAR REACTIVE OXYGEN 794 
SPECIES (ROS) LEVELS were determined by CM-H2DCFDA dye (Invitrogen) labeling 795 
following manufacturers guidelines. GLUTAMINE SYNTHETASE ACTIVITY in living cells. The 796 
enzyme activity in living cells was determined by pulse-labeling the cells for 30 min with 2 797 
mM 15NH4Cl and subsequent determination of 
15N incorporation in intracellular glutamine 798 
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by gas chromatography - mass spectrometry GC-MS (see below). Similarly, GS activity 799 
was measured by pulse-labeling for 30 min with 0.5 mM [U-13C]-glutamic acid and 800 
subsequent tracing of 13C into glutamine by GC-MS. The 0.025 mM glutamine condition 801 
was added to this assay for the sole purpose of having a positive control  lowering 802 
external glutamine levels should increase GS activity  and are not in any way reflecting 803 
maximal GS activity. Background signals were determined by pre-incubating the cells with 804 
the GS inhibitor MSO. As an independent manner (not relying on labeling one of the 805 
immediate substrates (NH4
+ or glutamate)) to determine GS activity, we performed steady 806 
state labeling of ECs with [U-13C]-glucose (5.5 mM) and determined carbon contribution to 807 
α-ketoglutarate, glutamate and glutamine (for labeling scheme see Extended Data Fig. 5f). 808 
Prior to derivatization for GC-MS analysis, cells were washed with ice-cold 0.9% NaCl and 809 
extracted in ice cold 80/20 methanol/water. GLUTAMINE UPTAKE ASSAY: Dynamic [U-13C]-810 
glutamine uptake assays were performed as follows: 2.5 x 105 cells/well were seeded in 6 811 
well plates and pulse-labeled for 0, 0.5,10, 20 and 30 min with the regular M199 culture 812 
medium containing 0.6 mM [U-13C]-glutamine instead of the regular 0.6 mM unlabeled 813 
glutamine. The 0 min time point represents an absolute negative control for which extracts 814 
were made from ECs that were never treated with tracer-containing medium. For the 0.5 815 
min time point, the labeled medium was put on the cells and immediately aspirated (all 816 
together taking 0.5 min). At all time points, cells were thoroughly washed twice with ice-817 
cold 0.9% NaCl to ensure complete removal of tracer-containing medium. Cellular extracts 818 
were then made in ice-cold 80/20 methanol/water, prior to derivatization for GC-MS 819 
measurements. Alternatively, cells were incubated with 0.5 µCi ml-1 [U-14C]-L-glutamine for 820 
10 min after which they were washed at least three times with ice-cold PBS. The last PBS 821 
wash was collected and checked for residual radioactivity. Cells were then lysed with 200 822 
µl 0.2 N NaOH and lysates were neutralized with 20 µl 1 N HCl and used for scintillation 823 
counting. [3H]-THYMIDINE INCORPORATION: Proliferation was determined by labeling the cells 824 
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with 1 µCi ml-1 [3H]-thymidine for 2 h, followed by fixation in 100% ethanol for 15 min, 825 
precipitation with 10% trichloroacetic acid and finally lysis in 0.1 N NaOH. Scintillation 826 
counting was used to assess the amount of [3H]-thymidine incorporated into the DNA. 827 
ENERGY CHARGE ASSESSMENT: 1.5 x 106 cells were collected in 100 µl ice cold 0.4 M 828 
perchloric acid containing 0.5 mM EDTA. pH was adjusted with 100 µl of 2 M K2CO3. 100 829 
µl of the mixture was subsequently injected onto an Agilent 1260 HPLC with a C18-830 
Symmetry column (150 x 4.6 mm; 5 mm; Waters), thermostated at 22.5 °C. Flow rate was 831 
kept constant at 1 ml min-1. A linear gradient using solvent A (50 mM NaH2PO4, 4 mM 832 
tetrabutylammonium, adjusted to pH 5.0 with H2SO4) and solvent B (50 mM NaH2PO4, 4 833 
mM tetrabutylammonium, 30% CH3CN, adjusted to pH 5.0 with H2SO4) was accomplished 834 
as follows: 95% A for 2 min, from 2 to 25 min linear increase to 100% B, from 25 to 27 min 835 
isocratic at 100% B, from 27 to 29 min linear gradient to 95% A and finally from 29 to 35 836 
min at 95% A. ATP, ADP and AMP were detected at 259 nm. SEAHORSE EXTRACELLULAR 837 
FLUX MEASUREMENTS: ECs were seeded at 1.5 x 105 cells per well on Seahorse XF24 838 
tissue culture plates (Seahorse Bioscience Europe). Oxygen consumption (OCR) 839 
measurements were performed at 6 min intervals (2 min mixing, 2 min recovery, 2 min 840 
measuring) in a Seahorse XF24 device (XF Reader 1.8.1.1 software). Consecutive 841 
treatments with oligomycin (1.2 ȝM final), FCCP (5 ȝM final) and antimycin A (1 ȝM final) 842 
were performed to allow quantification of ATP-coupled OCR (OCRATP) and maximal 843 
respiration, next to basal OCR (OCRbas). GLYCOLYTIC FLUX: ECs were cultured for 6 h in 844 
medium containing 0.4 mCi ml-1 [5-3H]-D-glucose (Perkin Elmer) after which supernatant 845 
was transferred into glass vials sealed with rubber stoppers. 3H2O was captured in 846 
hanging wells containing a Whatman paper soaked with H2O over a period of 48 h at 37 847 
°C to reach saturation 1. Then the paper was used for liquid scintillation counting 848 
(QuantaSmart TM V4 PerkinElmer). 14C-GLUCOSE OXIDATION: ECs were incubated for 6 h 849 
in medium containing 0.55 mCi ml-1 [6-14C]-D-glucose. After that, 250 ȝl of 2 M perchloric 850 
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acid was added to each well to stop cellular metabolism and to release 14CO2, which was 851 
captured overnight at room temperature in 1x hyamine hydroxide-saturated Whatman 852 
paper. The radioactivity in the paper was determined by liquid scintillation counting 853 
(QuantaSmart TM V4 PerkinElmer) 1. 14C-GLUTAMINE OXIDATION: ECs were incubated for 6 854 
h with medium containing 0.5 mCi ml-1 [U-14C]-glutamine. 250 ml of 2 M perchloric acid 855 
was added to the cells to stop cellular metabolism and release 14CO2. Trapping of 
14CO2 856 
occurred as described above for glucose oxidation 1. 857 
PROTEIN (AUTO)PALMITOYLATION DETECTION: IN VITRO PALMITOYLATION (CLICK REACTION-858 
BASED): Purified bacterial GS protein was incubated with the indicated concentration of 859 
palmitoyl alkyne-coenzyme A (Cayman Chemical) for 6 h at room temperature. The GS 860 
protein was then denatured by the addition of SDS. A click reaction with azide-biotin was 861 
performed to label the palmitoylated proteins 25. Palmitoylated proteins were detected by 862 
SDS-PAGE followed by blotting with streptavidin-horseradish peroxidase. FLUORESCENCE-863 
BASED COA RELEASE DETECTION: During autopalmitoylation of proteins, palmitate is 864 
transferred from palmitoyl-CoA to the protein thereby releasing reduced CoA. Į-865 
Ketoglutarate dehydrogenase can use CoA to convert Į-ketoglutarate to succinyl-CoA, a 866 
reaction that features reduction of NAD+ to fluorescent NADH29. In brief, recombinant 867 
human GS was incubated with palmitoyl-CoA in MES buffer at physiological pH for at least 868 
1 h at 30 °C. The volume was then adjusted to 200 µl in 50 mM sodium phosphate buffer 869 
(pH 6.8) containing 2 mM Į-ketoglutaric acid, 0.25 mM NAD+, 0.2 mM thiamine 870 
pyrophosphate, 1 mM EDTA, 1 mM DTT and 32 mU Į-ketoglutarate dehydrogenase. 871 
NADH levels were measured at 20 min after initiation of the reaction on a VICTOR plate 872 
reader (340 nm excitation  465 nm emission). The experiment was performed in two 873 
directions: either with varying doses of palmitoyl-CoA for a fixed amount of recombinant 874 
GS or with varying amounts of recombinant GS for a fixed concentration of palmitoyl-CoA 875 
(40 µM). AFFINITY CHROMATOGRAPHY: A previously published protocol was used to 876 
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determine cell-free binding of recombinant human GS to palmitoyl-CoA agarose30. A total 877 
of 50 ȝl of immobilized palmitoyl-CoA-agarose was equilibrated with 20 mM Tris-HCl (pH 878 
8.4)/120 mM NaCl. The beads were incubated with 40 ȝg of recombinant human GS in a 879 
final volume of 200 µl for 2 h at room temperature on a rotatory system. Beads were 880 
pelleted and 20 µl of the supernatant was collected as the flow through (FT) fraction. 881 
Beads were then washed eight times with 500 µl of 20 mM Tris-HCl (pH 8.4)/120 mM NaCl 882 
buffer. 20 µl of the last wash fraction was collected as fraction W8. Beads were then eluted 883 
with SDS loading buffer and heated for 15 min at 60 °C. 2 µg of recombinant protein was 884 
used as input fraction (IF).  IF, FT, W8 and SDS-eluate were analysed by immunoblotting 885 
for GS. IN CELL LABELING: In cell labeling experiments were performed essentially as 886 
described previously 25. HEK-293T cells were transfected with the indicated expression 887 
plasmids. Twenty-four h after transfection, the medium was replaced with DMEM + 10% 888 
dialyzed FBS containing the indicated probes (50 µM 16C-YA or 50 µM 16C-BYA). After 889 
18 h, cell lysates were collected by incubation of the cells on ice for 15 min in lysis buffer 890 
(50 mM TEA-HCl (pH=7.4), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 891 
0.1% SDS and 5 mM PMSF) followed by centrifugation for 10 min at 15,000 g.  Equal 892 
amounts of protein were then used for a click reaction with azide-biotin. For labeling with 893 
17-ODYA, FLAG-RHOJ overexpressing ECs were incubated overnight with 17-ODYA (50 894 
µM) in M199 supplemented with 3.6% fatty acid free BSA, 10% dialyzed FBS and 5 mM 895 
sodium pyruvate. Cells were washed with ice-cold PBS and lysed in NaP lysis buffer (0.2 896 
M Na2HPO4.2H2O, 0.2 M NaH2PO4.2H20, 1 M NaCl, 10% NP40). 2 µg of anti-Flag 897 
antibody was conjugated to 20 µl of dynabeads protein G (Thermofisher) for 1 h at RT. 898 
After washing the beads twice with NaP lysis buffer, at least 500 µg of protein was added 899 
to the beads for 3 h at 4 °C. Then beads were washed 3 times with NaP lysis buffer and 900 
resuspended in 20 µl of resuspension buffer (4% SDS, 50 mM TEA, 150 mM NaCl). The 901 
click reaction was initiated by adding 0.5 ȝl of 5 mM tetramethylrhodamine azide (TAMRA) 902 
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(Lumiprobe), 0.5 ȝl 50 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl), 0.5 ȝl 903 
10 mM tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) and 2.4 µl of 5 mM freshly 904 
made ascorbic acid. Samples were then incubated for 1 h at 37 °C in the dark. Sample 905 
buffer (9.4 µl) and reducing agent (3.7 µl) were added to stop the reaction. After 10 min at 906 
room temperature in the dark, samples were frozen at -80 °C or run on a 10% Bis-TRIS 907 
gel in MES buffer. In-gel fluorescence was imaged with Typhoon TM FLA 9500 V1.0. 908 
STREPTAVIDIN-PULLDOWN: After click reaction with azide-biotin, free azide-biotin was 909 
removed from the samples by centrifugal filtration column (Millipore). The samples were 910 
then incubated with streptavidin-conjugated beads for 1 h at room temperature. After 911 
washing with PBS-T, proteins were eluted from the beads by incubation in elution buffer 912 
(95% formamide, 10 mM EDTA (pH=8.0)) at 95 ιC for 5 min. ACYL-RESIN-ASSISTED 913 
CAPTURE (ACYL-RAC) in which free cysteine thiols are chemically blocked and palmitoylated 914 
cysteines are exposed and captured by a resin, was performed with the CAPTUREomeTM 915 
S-Palmitoylated Protein Kit (Badrilla) with minor adaptations to the manufacturers 916 
guidelines. 500 µg of protein were incubated for 4 h in 500 µl of thiol blocking reagent (to 917 
block free thiols). Proteins were precipitated with ice-cold acetone and afterwards 918 
solubilized with 300 µl of binding buffer and spun down. After protein quantification, 30 µg 919 
was kept as total input fraction (IF), and equal amounts of protein were incubated for 2.5 h 920 
with (or without to obtain the negative control preserved bound fraction (pBF)) a thioester 921 
linkage specific cleavage reagent to cleave the thioester bond. Newly liberated thiols were 922 
captured with CAPTUREomeTM resin. The resin was spun down and the supernate was 923 
collected as the cleaved unbound fraction (cUF) to check if the proteins of interest were 924 
indeed completely depleted from the thioester cleavage reagent (meaning efficient capture 925 
of the free thiols by the resin). After thorough washing of the resin, captured proteins 926 
(cleaved bound fraction (cBF)), were eluted with reductant and analyzed together with the 927 
IF, cUF and pBF by SDS-PAGE followed by immunoblotting.  928 
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 929 
GC-MS ANALYSIS:  Metabolites from cells were extracted in 800 µl 80% methanol (at -80 930 
°C). Next the extracts were centrifuged at 4 °C for 15 min at 20,000 x g and the 931 
supernatants were dried in a vacuum centrifuge. 25 µl of a 2% methoxyamine 932 
hydrochloride solution (20 mg dissolved in 1 ml pyridine) was added to the dried fractions 933 
which were then incubated at 37 °C for 90 min. Then 75 ȝl of N-tert-butyldimethylsilyl-N-934 
methyltrifluoroacetamide with 1% N-tert-butyldimethyl-chlorosilane (Sigma-Aldrich) was 935 
added and the reaction was carried out for 30 min at 60 °C. Reaction mixtures were 936 
centrifuged for 15 min at 20,000 x g at 4 °C in order to remove insolubilities and the 937 
supernatant was transferred to a glass vial with conical insert (Agilent). GC-MS analyses 938 
were performed on an Agilent 7890A GC equipped with a HP-5 ms 5% Phenyl Methyl 939 
Silox (30 m - 0.25 mm i.d. - 0.25 ȝm; Agilent Technologies) capillary column, interfaced 940 
with a triple quadrupole tandem mass spectrometer (Agilent 7000B, Agilent Technologies) 941 
operating under ionization by electron impact at 70 eV. The injection port, interface and ion 942 
source temperatures were kept at 230 °C. Temperature of the quadrupoles was kept at 943 
150 °C. The injection volume was 1 ȝl, and samples were injected at 1:10 split ratio. 944 
Helium flow was kept constant at 1 ml min-1. The temperature of the column started at 100 945 
°C for 5 min and increased to 260 °C at 2 °C min-1. Next, a 40 °C min-1 gradient was 946 
carried out until the temperature reached 300 °C. After the gradient, the column was 947 
heated for another 3 min at 325 °C. The GC-MS analyses were performed in Single Ion 948 
Monitoring (SIM) scanning for the isotopic pattern of metabolites. 949 
LC-MS ANALYSIS: POLAR METABOLITES were extracted using 250 µl of a 50-30-20 950 
(methanol-acetonitrile-10 mM ammonium acetate pH 9.3 containing 2 µM of deuterated 951 
(d27) myristic acid as internal standard) extraction buffer. Following extraction, precipitated 952 
proteins and insolubilities were removed by centrifugation at 20,000 x g for 20 min at 4 °C. 953 
The supernatant was transferred to the appropriate mass spectrometer vials. 954 
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Measurements were performed using a Dionex UltiMate 3000 LC System (Thermo 955 
Scientific) in-line connected to a Q-Exactive Orbitrap mass spectrometer (Thermo 956 
Scientific). 15 µl of sample was injected and loaded onto a Hilicon iHILIC-Fusion(P) 957 
column (Achrom). A linear gradient was carried out starting with 90% solvent A (LC-MS 958 
grade acetonitrile) and 10% solvent B (10 mM ammonium acetate pH 9.3). From 2 to 20 959 
mins the gradient changed to 80% B and was kept at 80% until 23 min. Next a decrease to 960 
40% B was carried out to 25 min, further decreasing to 10% B at 27 min. Finally, 10% B 961 
was maintained until 35 min. The solvent was used at a flow rate of 200 µl min-1, the 962 
columns temperature was kept constant at 25 °C. The mass spectrometer operated in 963 
negative ion mode, settings of the HESI probe were as follows: sheath gas flow rate at 35, 964 
auxiliary gas flow rate at 10 (at a temperature of 260 °C). Spray voltage was set at 4.8 kV, 965 
temperature of the capillary at 300 °C and S-lens RF level at 50. A full scan (resolution of 966 
140,000 and scan range of m/z 70-1050) was applied. For the data analysis, we used an 967 
in-house library and metabolites of interest were quantified (area under the curve) using 968 
the XCalibur 4.0 (Thermo Scientific) software platform.  969 
IN VITRO ASSAYS: ENDOTHELIAL SPHEROID CAPILLARY SPROUTING was performed following 970 
established protocols 1,2. To form the spheroids, ECs were cultured overnight in hanging 971 
drops in EGM2 medium with methylcellulose (Sigma-Aldrich; 20 %volume of a 1.2% 972 
solution of methylcellulose 4000 cP). Spheroid sprouting entails both EC proliferation and 973 
migration. To have a clean view on the migration aspect in sprouting, we also included 974 
conditions in which we blocked EC proliferation prior to sprout formation. More in 975 
particular, mitotic inactivation was achieved by adding mitomycin C (1 µg ml-1) to the 976 
medium. To induce sprouting, spheroids were embedded in a collagen gel and incubated 977 
for 20 h. If required, chemical compounds (Fasudil at 10 µM, H1152 at 1 µM and Y26732 978 
at 10 µM) were added during the collagen gel incubation step. Spheroids were then fixed 979 
with 4% paraformaldehyde and imaged under phase contrast illumination with a Motic AE 980 
7/18/2018 39
31 microscope (Motic Electric Group Co Ltd) or a Leica DMI6000B microscope (Leica 981 
Microsystems). Phase contrast images were used to quantify the number of sprouts per 982 
spheroid and the total sprout length (cumulative length of all sprouts on a spheroid). 983 
Spheroid body circumference was measured to correct for differences in size of the 984 
spheroid. Per experiment (ie per individual HUVEC isolation) at least 10 spheroids per 985 
condition were analyzed.  SCRATCH WOUND ASSAYS: 75,000 HUVECs were seeded in 24-986 
well format and were allowed to reach confluency over the next 24 h. At time T0 the 987 
confluent monolayer was scratched with a 200 µl pipet tip and photographed. The cells 988 
were further incubated for the indicated times and photographed again at time point Tx. 989 
Gap area at T0 minus gap area at Tx was measured with ImageJ and expressed as % 990 
migration distance. Per well, three non-overlapping regions along the scratch were 991 
analyzed. Much like the spheroid sprouting, scratch wound healing is a combined readout 992 
for EC migration and proliferation. Therefore, we also included conditions in which the ECs 993 
were pre-treated with mitomycin C (1 µg ml-1) to rule out the effect of proliferation. BOYDEN 994 
CHAMBER ASSAYS: 50,000 HUVECs were seeded on 0.1% gelatin-coated transwells and 995 
allowed to adhere. Then, the transwells were washed and refed with medium containing 996 
only 0.1% FBS and placed in bottom wells containing medium with 5% FBS as a pro-997 
migratory stimulus. 16 h later, transwells were processed and analysed for numbers of 998 
migrated cells. Pre-treatment with mitomycin C (see above) was applied. VELOCITY OF 999 
RANDOM MOVEMENT was assessed on HUVECs that were sparsely seeded on glass bottom 1000 
24-well plates. Time-lapse videos were generated by confocal image acquisition at 4 min 1001 
intervals. Velocity of movement was determined by tracking nucleus position in function of 1002 
time (µm h-1) (Tracking Tool TM, Gradientech AB, Uppsala, Sweden). Per condition, on 1003 
average 2 or 3 individual cells were traced in each biological repeat. LAMELLIPODIAL AREA 1004 
was measured on sparsely seeded phalloidin-stained ECs with Leica MM AF 1005 
morphometric analysis software (Leica Microsystems, Mannheim, Germany) with in-house 1006 
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developed journals and is expressed in percent of total cell area. Treatment with MSO (1 1007 
mM), Y27632 (10 µM), Fasudil (10 µM), H1152 (1 µM), ML7 (15 µM) and peptide 18 (15 1008 
µM) were done 24 h prior to analysis of the cells. Per experimental condition, a minimum 1009 
of ten individual cells was analyzed. STAINING AND QUANTIFICATION OF VE-CADHERIN 1010 
JUNCTIONS: VE-cadherin staining and quantification of junctional length and gap index was 1011 
performed as previously described 31. First, the total junctional length (100%) was 1012 
determined by summing up all segments, then the sum of all continuous segments was 1013 
calculated as the percentage of total junctional length. The percentage difference between 1014 
total and continuous represents the discontinuous length. Gap size index (intercellular gap 1015 
area/cell number) was determined with the formula ([intercellular gap area/total cell area] 1016 
×1,000)/cell number. Junctional lengths, intercellular gap area, and total cell area were 1017 
defined manually with ImageJ. For each condition, a minimum of 10 fields was quantified 1018 
(10-15 cells per field on average) per experiment, and data shown represent the mean of 1019 
at least 3 independent experiments. TRANS ENDOTHELIAL ELECTRICAL RESISTANCE (TEER): 1020 
50,000 ECs were seeded on 6.5 mm 0.1% gelatin-coated polyester transwells, 0.4 ȝm 1021 
pore size (Costar ref. 3470, Sigma-Aldrich). The electrical resistance was measured with 1022 
an Endhome-6 electrode (World Precisions Instruments) connected to an EVOM2 1023 
voltohmmeter (World Precisions Instruments). Gelatin-coated wells without cells were 1024 
used to measure the intrinsic electrical resistance of the inserts for background 1025 
subtraction. Measurements were performed every day for 4 consecutive days, with at least 1026 
2 measurements per condition. 1027 
ACTIN DYNAMICS AND RHO (KINASE) ACTIVITY ASSAYS: LATRUNCULIN WASH-OUT: ECs were 1028 
treated with latrunculin B (100 ng ml-1) for 30 min and were then washed three times with 1029 
culture medium. The cells were fixed at the indicated time points and stained with 1030 
phalloidin to visualize actin stress fibers. THE F-/G-ACTIN RATIO in GSKD vs control ECs was 1031 
determined in 4% paraformaldehyde-fixed cells which were permeabilized for 10 min in 1032 
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PBS with 0.2% Triton X-100 and stained with phalloidin-Alexa 488 and deoxyribonuclease 1033 
I-Alexa 594 (1:200) 32. Fluorescence intensities were quantified with ImageJ and were 1034 
based on gray values. On average, ten individual cells were analyzed per experimental 1035 
condition. For RHOJ ACTIVITY measurements, cells were lysed in buffer containing 50 mM 1036 
Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2, protease inhibitors and 0.1 1037 
µg µl-1 biotinylated CRIB-peptide. After spinning down for 4 min at 14,000 rpm at 4 °C, 50 1038 
µl streptavidin-coated beads were added to the lysates. Subsequently, samples were 1039 
rotated for 30 min at 4 °C, beads were washed 4 times in the above buffer after which they 1040 
were boiled for 5 min in reducing agent and loading buffer 33. As negative controls in this 1041 
assay, we used lysates from RHOJKD ECs, a streptavidin beads only-condition and lysates 1042 
in which the biotinylated CRIB-peptide was replaced by an irrelevant biotinylated protein 1043 
(Fig. 4c). RHOA/B/C ACTIVITY was determined with GST-Rhotekin pull down assays 1044 
following previously established protocols 34. ROCK ACTIVITY was assayed by determining 1045 
phosphorylation of the ROCK target myosin light chain 2 (MLC2) on Western Blot or by 1046 
immunostaining. Fluorescence intensities from immunostainings were quantified with 1047 
ImageJ and were based on gray values. 1048 
CONFOCAL AND HIGH RESOLUTION IMAGING: CONFOCAL IMAGING was performed on a Zeiss 1049 
LSM 510 Meta NLO or Zeiss LSM 780 confocal microscope (oil objectives: x 40 with NA 1050 
1.3, x 63 with NA 1.4, x 100 with NA 1.3) with ZEN 2011 software (Carl Zeiss, Munich, 1051 
Germany). Within individual experiments, all images across different experimental 1052 
conditions were acquired with the same settings. DORA RHOA BIOSENSOR FRET IMAGING: 1053 
RHOA activity was measured in living HUVECs by monitoring yellow fluorescent protein 1054 
(YFP) FRET over donor cyan fluorescent protein (CFP) intensities as described previously 1055 
35. In brief, a Zeiss Observer Z1 microscope, with a Chroma 510 DCSP dichroic splitter, 1056 
two Hamamatsu ORCA-R2 digital CCD cameras and an attached dual camera adaptor 1057 
(Zeiss) controlling a 510 DCSP dichroic mirror, was used for simultaneous monitoring of 1058 
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CFP and YFP emissions using filter sets ET 480/40 and ET 540/40m (Chroma 1059 
Technology, Rockingham, USA), respectively. To excite the CFP donor, ET 436/20x and 1060 
455 DCLP dichroic mirror was used (Chroma). For FRET/CFP ratiometric processing, CFP 1061 
and YFP images were processed using the MBF ImageJ collection. The images were 1062 
background-subtracted, aligned and a threshold was applied. Finally, the FRET/CFP ratio 1063 
was calculated and a custom lookup table was applied to generate a color-coded image, in 1064 
which white and red colors illustrate high and blue colors illustrate low RHOA activities. 1065 
BIFC IMAGING AND QUANTIFICATION: BiFC was evaluated using a laser scanning microscope 1066 
(Fluoview FV1000, Olympus, Tokyo, Japan) equipped with a UPLSAPO 60x Oil objective 1067 
(NA1.35). Before imaging cells were fixed with 4 % (v/v) paraformaldehyde and stained 1068 
with DAPI (1:1,000 dilution, Invitrogen). A 488-nm laser was used for exciting EGFP while 1069 
DAPI was excited using a 405-nm laser. A DM405/488/559/635 polychroic mirror was 1070 
used to guide the excitation lasers to the sample. Fluorescence images of fixed cells were 1071 
acquired using a sampling speed of 4 ȝs pixel-1. Emission light was collected at 430-470 1072 
and 500-550 nm, for DAPI and EGFP, respectively. The images were acquired with a pixel 1073 
size of 207 nm (1,024 x 1,024 pixels). BiFC was first established in HEK cells expressing 1074 
GS-EGFP1/2 and RHOJ-EGFP2/2 from one expression vector, with a construct 1075 
overexpressing an unfused N-terminal EGFP half-site together with RHOJ coupled to the 1076 
C-terminal EGFP half-site as a negative control (data not shown). To determine the effect 1077 
of deleting the first 20 amino acids in RHOJ on BiFC in ECs, separate expression 1078 
constructs for GS-EGFP1/2, RHOJ-EGFP2/2 and ΔN-RHOJ-EGFP2/2 were used (Ext. Data 1079 
Fig. 7e). Quantification of expression efficiency was done using a home-built routine in 1080 
Matlab®. TIRF MICROSCOPY: A home build setup based on an inverted microscope (IX83, 1081 
Olympus) was used to detect single molecules under total internal reflection (TIRF) mode. 1082 
The setup was equipped with an Electron Multiplying-CCD cameras (ImagEM C9100-13; 1083 
Hamamatsu Photonics, Hamamatsu, Japan) and an APON 60XOTIRF objective lens (NA 1084 
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1.49, Olympus). The GS-mEos3.2 molecules were excited with a 561-nm line from a 1085 
DPSS laser (200 mW; Coherent Inc., Santa Clara, California) and converted with a 405-1086 
nm line from a diode laser (Cube, 100 mW; Coherent Inc., Santa Clara, California). Before 1087 
being expanded, the laser lines were combined using a 405bcm dichroic mirror. The laser 1088 
lines were guided onto the sample by a dichroic mirror, z488/561/633rpc. The 1089 
fluorescence of the red of mEos3.2 form was detected through a long pass filter 572 1090 
(HQ572LP), in combination with a band pass filter HQ590M40-2P. All the filters were 1091 
purchased from Chroma Inc. Time-lapse fluorescence images were recorded with 1092 
continuous illumination at a 62.5 Hz acquisition rate (16 ms per frame). SINGLE PARTICLE 1093 
TRACKING (SPT): For calculation of single molecule coordinates the program 'Localizer' 1094 
running from Matlab was used 36. After localization, the positions of a molecule detected in 1095 
consecutive frames are connected to reconstruct a trajectory using home-developed 1096 
software in Matlab. Coordinates presented in consecutive frames are linked to form a 1097 
single trajectory when they uniquely appear in a distance smaller than 856 nm 1098 
(corresponding to 8 pixels). Trajectories with at least 3 steps were analyzed using 1099 
variational Bayes single particle tracking analysis (vbSPT), a software package for 1100 
analysis of single particle diffusion trajectories, where the diffusion constants switch 1101 
randomly according to a Markov process 37.  1102 
MICE: GSECKO MICE: To obtain inducible EC-specific GS knock-out mice, GSlox/lox mice 38 1103 
were intercrossed with VECadherin-CreERT2 39 or with Pdgfb-CreERT2 40 mice and named 1104 
GSvECKO and GSpECKO respectively. Correct Cre-mediated excision of the loxed GS 1105 
segment in tamoxifen-treated GSECKO mice was confirmed via PCR analysis of genomic 1106 
DNA (Extended Data Fig. 1d-e). GENERATION OF GS+/GFP CHIMERAS : Blastocysts were 1107 
collected from superovulated C57BL/6 females at post-coital day 3.5 and were cultured for 1108 
5-8 days in ES cell culture medium consisting of Knockout DMEM medium (Invitrogen), 1109 
with 2 mM L-glutamine, fetal bovine serum (Hyclone, ThermoScientific), MEM non-1110 
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essential amino acids 100X (Invitrogen), 0.01 mM ȕ-mercaptoethanol (Sigma-Aldrich), 1 1111 
mM sodium pyruvate (Invitrogen), 100 U ml-1 penicillin, 100 µg ml-1 streptomycin, and 1112 
2,000 U ml-1 Leukemia Inhibitory Factor (Merck, Millipore). Afterwards, the inner cell mass 1113 
was selectively removed from the trophectoderm, trypsinized and replated on a Mitomycin 1114 
C-arrested MEF feeder monolayer. ES cells were fed every day and passaged every 2-4 1115 
days onto new feeder cells. GS+/GFP ES cells (E14IB10 ES cell line) 6 were injected into 1116 
C57BL/6 blastocysts and high chimeric pups were killed at P5 for detection of GFP in the 1117 
retinal microvasculature. 1118 
IN VIVO MODELS: ANALYSIS OF DORSAL DERMAL BLOOD VESSEL NETWORK: From E11.5 to E13.5 1119 
after vaginal plug, GSvECKO pregnant dams were treated with tamoxifen (50 mg kg-1) by 1120 
oral gavage. At E16.5 they were euthanized by cervical dislocation after which embryos 1121 
were dissected from the uterus. Yolk sacs were collected, washed with PBS and used for 1122 
genotyping of the embryos. The embryos were fixed for 10 min in 1% PFA prior to 1123 
dissection of the dorsal skin. The epidermal and dermal layers were separated under a 1124 
dissection microscope. Dissected back skins were permeabilized overnight (0.5% Triton X-1125 
100, 0.01% sodium deoxycholate, 1% bovine serum albumin, 0.02% sodium azide) prior to 1126 
whole-mount immunostaining with CD31. To systematically analyze the same region for 1127 
each embryo, 1 rectangular confocal image (1,700 x 1,100 µm) was taken at the anterior 1128 
side of the skin specimen with the upper longer side of the rectangle placed on the 1129 
midline. Within each rectangular picture the number of branch points was determined with 1130 
the cell counter tool in ImageJ in 6 ROIs (250 x 250 µm), 3 in the top half and 3 in the 1131 
bottom half of the rectangle, not overlapping with the larger arteries and veins. NEONATAL 1132 
RETINAL ANGIOGENESIS: EC-specific GS deletion was obtained by IP administration of 1133 
tamoxifen (Sigma; 10 mg kg-1; dissolved in 1:10 EtOH:oil solution) once daily from P1 to 1134 
P3 in GSvECKO or once at P2 for GS
pECKO. For in vivo proliferation quantification, EdU (5-1135 
ethynyl-2´-deoxyuridine; Invitrogen) was injected IP 2 h before sacrifice. Unless stated 1136 
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otherwise, retinas were isolated at P5 as previously described 41 and fixed in 2% PFA for 2 1137 
h. Isolectin B4 (IB4), EdU, NG2 and ColIV stainings were performed as previously 1138 
described 1,2. Radial outgrowth of the vascular plexus, vascular area, branch points, 1139 
number of filopodia and number of distal sprouts were analysed on isolectin IB4-stained 1140 
retinas (see below) with Image J. Numbers of branch points and EdU+ ECs were quantified 1141 
in 200 x 200 µm ROIs; per retina 12 ROIs were placed at the front of the vascular plexus 1142 
and 8 ROIs were placed more towards the center of the plexus. Filopodia and distal 1143 
sprouts were quantified on ten high magnification (63x) images per retina, each 1144 
representing approximately 200 µm of utmost vascular front. For analysis of the retinal 1145 
vasculature at P21 (3 week-old) and P42 (6 week-old) mice underwent the same 1146 
tamoxifen treatment regimen as for analyses at P5. In addition, different tissues were 1147 
collected from P42 mice for endoglin and CD34 staining to study blood vessels in different 1148 
vascular beds. OXYGEN INDUCED RETINOPATHY: Oxygen induced retinopathy (ROP) was 1149 
induced by exposing C57BL/6 pups to 70% oxygen from P7-P12. Pups were then returned 1150 
to normoxia and injected daily with 20 mg kg-1 MSO. At P17, pups were euthanized and 1151 
eyes were enucleated, fixed in 4% PFA and retinal flatmounts were stained for isolectin B4 1152 
2,3. MSO-treated animals retained normal behavior notwithstanding observable weight 1153 
loss. Mosaic tile images were captured using the inverted Leica DMI6000B 1154 
epifluorescence microscope (Leica, Manheim, Germany) and analysis of the vascular tuft 1155 
area (the complete retina was analyzed, no ROIs were used) and the vaso-obliterated 1156 
area was performed with NIH Image J software and are expressed as percentage of the 1157 
total retinal area. CORNEAL (MICRO-)POCKET ASSAY (CPA) to induce neovascularization of 1158 
the avascular cornea was performed as previously described 42. In brief, in the eyes of 8 1159 
week-old C57BL/6 mice, a lamellar micropocket was dissected toward the temporal limbus 1160 
to allow placing of a basic fibroblast growth factor (bFGF)-containing pellet on the corneal 1161 
surface. Five days after implanting the pellets, the mice were sacrificed, the eyes were 1162 
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enucleated and the corneas were excised and fixed in 70% ethanol prior to CD31 antibody 1163 
staining. After staining, the corneas were flat-mounted and imaged on a Zeiss LSM 780 1164 
confocal microscope. CD31+ area was measured in ImageJ after thresholding the signal 1165 
and is expressed as % of total cornea area. Production of the pellets was done as 1166 
previously described 42. The pellets contained 20 ng bFGF and the concentration of MSO 1167 
in the initial solution from which the pellets were made was 10 mM. IMIQUIMOD-INDUCED 1168 
SKIN INFLAMMATION: Ten week old female Balb/C mice received a daily topical dose of 5% 1169 
imiquimod cream (62.5 mg) on their shaved backs for four days to induce skin 1170 
inflammation 3. 1 h after each administration of the cream, the same skin area was treated 1171 
either with Vaseline® jelly or Vaseline® jelly containing MSO (low dose: 20 mg kg-1; or high 1172 
dose: 40 mg kg-1). The MSO treatment did not affect bodyweight of the mice. Skins and 1173 
spleens were collected and fixed in 4% PFA. Paraffin sections of skins were stained for 1174 
CD105 (R&D Systems) and H&E. Images were captured with a Leica DMI6000B 1175 
microscope (Leica microsystems, Mannheim, Germany). Per animal, ten images 1176 
representing different locations along the total length of the skin specimen were analyzed 1177 
for CD105+ area. MILES VASCULAR PERMEABILITY ASSAY: 8 week old female Balb/C mice 1178 
were treated for 3 consecutive days with 20 mg kg-1 day-1 MSO or with vehicle prior to 1179 
injection with 300 µl 0.5 % Evans blue dye. The inflammatory irritant mustard oil (0.25 ml 1180 
allyl isothiocyanate in 4.75 ml mineral oil) was applied on one of the ears with a cotton 1181 
swab to induce vascular permeability. Mineral oil as a control was applied on the other ear. 1182 
After 15 min, again mustard oil/mineral oil was applied on the ear for 30 min, after which 1183 
the circulation was flushed with saline for 3 min and mice were perfused with 1 % PFA in 1184 
50 mM citrate buffer (pH=3.5) for 2 min. Ears were cut and minced in formamide and 1185 
incubated at 55 °C overnight to extract the Evans blue from the tissue. Quantification of 1186 
the dye was performed by a spectrophotometrical optical density measurement at 620 nm. 1187 
HEMATOLOGICAL PROFILING IN 6 WEEK-OLD MICE was performed with a Cell Dyn 3700 device 1188 
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(Abbott Diagnostics) according to the manufacturers guidelines. Plasma measurements 1189 
for different liver/inflammation parameters were performed in the clinical laboratory of the 1190 
university hospital of Leuven. Prior randomization was not applicable for any of the above 1191 
mouse models given that all animal treatments were done in baseline conditions. No 1192 
statistical methods were used to predetermine the sample size. For all mouse 1193 
experiments, data analysis was done by researchers blinded to the group allocation. All 1194 
animal procedures were approved by the Institutional Animal Care and Research Advisory 1195 
Committee of the University of Leuven. 1196 
IN SILICO SCREENING FOR PALMITOYLATION SITES: The human RHOJ protein sequence was 1197 
screened for putative palmitoylation sites on the SwissPalm website 22 entering RHOJ as 1198 
the protein name. 1199 
MODELING AND SIMULATIONS: The GS models were built starting from X-ray crystallographic 1200 
structures retrieved from the Protein Data Bank (entry 2OJW for human GS and 1FPY for 1201 
bacterial GS). All simulations were run with Gromacs 5.1.443 and the  Amber FF14SB44 1202 
force field, while palmitoyl-CoA was parametrized with GAFF and the point charges were 1203 
calculated with Gaussian 0945 at the Hartree-Fock level with a 6-31G* basis set. The 1204 
different models were then embedded in a TIP3P water box, counter ions were added to 1205 
ensure the overall charge neutrality. An initial 2,000 steps of steepest descent and 500 1206 
steps of conjugated gradient were applied to minimize the geometry and remove steric 1207 
clashes, followed by 10 ns of isothermal-isobaric (NPT) equilibration. The Berendsen 1208 
barostat was applied to keep the pressure around 1 atm, while the temperature of 300K 1209 
was maintained throughout all the simulations with the V-rescale algorithm46. 500 ns long 1210 
molecular dynamics production runs were carried out for all the systems in the canonical 1211 
(NVT) ensemble, for a cumulative total of 2.5 ȝs. The particle mesh Ewald (PME)-Switch 1212 
algorithm was used for electrostatic interactions with a cut-off of 1 nm, and a single cut-off 1213 
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of 1.2 nm was used for Van der Waals interactions. Four simulations for human GS and 1214 
two for Salmonella typhimuriums GS were run by placing the CoA moiety close to the 1215 
adenosine binding site and allowing different initial positions for the palmitoyl tail. The CoA 1216 
head invariably docked and remained tightly bound to the adenine binding site in all 1217 
simulations. Among these, two favorable alternative arrangements (Extended Data Fig. 1218 
8b) for the tail were identified in both systems. In one of these conformations, the 1219 
beginning of the palmitate tail (from the point of view of the CoA moiety) approaches very 1220 
closely the conserved CYS209 (human residue numbering, Conformation A in Extended 1221 
Data Fig. 8b, details in Extended Data Fig. 8c), and in the other conformation 1222 
(Conformation B in Extended Data Fig. 8b, details in Extended Data Fig. 8d) it approaches 1223 
the conserved Ser65 and 75. 1224 
MULTIPLE SEQUENCE ALIGNMENTS: A multiple sequence alignment of the GS protein across 1225 
different species was performed with the Basic Local Alignment Search Tool (BLAST). The 1226 
algorithm matches sequences according to local similarity, by optimizing their Maximal 1227 
Segment Pair score (MSP). The 100 matches with the highest identity to the Homo 1228 
sapiens sequence surrounding amino acid C209 were taken from the UniProtKB/Swiss-1229 
Prot refined database. 1230 
STATISTICAL ANALYSIS: Data represent mean±s.e.m. of pooled experiments unless 1231 
otherwise stated. Scatters in bar graphs represent the values of independent experiments 1232 
or individual mice. In case individual values are highly alike, scatter points overlap and 1233 
may no longer be visible as individual points. n values represent the number of 1234 
independent experiments performed or the number of individual mice phenotyped. 1235 
Statistical significance between groups was calculated with one of the following methods. 1236 
For comparisons to point-normalized data, a two-tailed one-sample t-test was used in 1237 
GraphPad Prism7. For pairwise comparisons, two-tailed unpaired t-tests were used in 1238 
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GraphPad Prism7. For multiple comparisons within one data set, one-way ANOVA with 1239 
Dunnetts multiple comparison (comparing every mean with the control mean rather than 1240 
comparing every mean with every other mean) was used in GraphPad Prism7. Mixed 1241 
model statistics (this test does not assume normality or equal variance) was used with the 1242 
experiment as random factor only in case confounding variation in baseline measurements 1243 
between individual EC isolations (for each experiment, ECs were freshly isolated from 1244 
individual human umbilicals) or mouse litters precluded the use of the above described 1245 
statistical tests. For this, R and the lme4 package were used; P values were obtained with 1246 
the Kenward-Roger F-test for small mixed effect model datasets. In the most severe 1247 
cases, the individual datapoints (each datapoint being the mean of the technical replicates 1248 
within an experiment or an individual animal) in the bar graphs have been color-coded per 1249 
experiment or per litter to show the baseline variation. Sample size for each experiment 1250 
was not pre-determined. A P value <0.05 was considered significant.  1251 
DATA AVAILABILITY: Fig.1, Fig. 4, Fig. 5, Extended Data Fig. 1, Extended Data Fig. 7 and 1252 
Extended Data Fig. 8 have associated raw data (uncropped blots and/or gel pictures) in 1253 
Supplemental Information Fig. 1. Fig. 1, Fig. 2, Extended Data Fig. 1 and Extended Data 1254 
Fig. 4 have associated raw data (Excel files) for all bar graphs representing data from 1255 
experiments involving mouse models. For the molecular modelling of palmitoyl-CoA 1256 
docking into GS, models and trajectories are available on Figshare (doi: 1257 
10.6084/m9.figshare.6575438). Any additional information required to interpret, replicate 1258 
or build upon the Methods or findings reported in the manuscript is available from the 1259 
corresponding author upon request. 1260 
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 1348 
LEGENDS TO EXTENDED DATA TABLES 1349 
EXTENDED DATA TABLE 1: WEIGHT, HEMATOLOGICAL AND BLOOD PLASMA 1350 
PARAMETERS FOR 6 WEEK-OLD GSVECKO MICE AND CONTROL LITTERMATES 1351 
Values are mean±s.e.m. of n=14 (control) vs n=17 (GSvECKO) animals. *P = 0.0232 vs 1352 
control, Students t test. WBCs, white blood cells; RBCs, red blood cells, AST, aspartate 1353 
amino transferase; ALT, alanine amino transferase; γ-GT, gamma-glutamyl transferase; 1354 
CRP; C-reactive protein. 1355 
 1356 
7/18/2018 53
EXTENDED DATA TABLE 2: ALIGNMENT OF THE AMINO ACID SEQUENCE 1357 
ENCOMPASSING THE C209 RESIDUE ACROSS DIFFERENT SPECIES. 1358 
Multiple sequence alignment showing the conservation of amino acid C209 (in red) in GS 1359 
across different species. Here the sequence alignment of 41 residues surrounding this 1360 
cysteine is shown for up to 100 of the closest sequence identity matches with Homo 1361 
sapiens GS obtained with BLAST from the UniProtKB/Swiss-Prot database. C209 is 1362 
mostly conserved across species and when not conserved it is often substituted by 1363 
residues (Ser or Thr) that can (in theory) be palmitoylated as well. In Escherichia coli 1364 
(shown at the bottom), for example, a Thr is found at the structurally equivalent position 1365 
(T210, highlighted in yellow). If for one and the same species multiple GS isoforms are 1366 
known, only the one with the highest % identity is shown. 1367 
 1368 
 1369 
 1370 
 1371 
 1372 
 1373 
LEGENDS TO EXTENDED DATA FIGURES  1374 
EXTENDED DATA FIGURE 1: GS KNOCK-OUT IMPAIRS VESSEL SPROUTING 1375 
a, GS mRNA levels in human umbilical vein ECs (HUVEC; n=9 donors), lung ECs (n=5), 1376 
colon ECs (n=4), liver ECs (n=3), human umbilical arterial ECs (HUAEC; n=2) and human 1377 
blood outgrowth ECs (BOEC (n=2); (mean±s.e.m.; *P <0.05 vs HUVEC, Students t test) 1378 
and in HEPG2 cells (mean±s.e.m.; n=3; *P <0.05 vs HUVEC, Students t test). b-c, 1379 
Western blot of GS protein levels in HUVECs and HEPG2 cells in medium containing 0.6 1380 
mM glutamine (+) or 0.025 mM glutamine (-) (b), and in isolated mouse liver ECs (mLiECs) 1381 
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and mouse astrocytes (c) (representative immunoblots of two independent experiments 1382 
are shown). d-e, Genomic organization of the loxed GS allele before and after Cre-1383 
mediated excision (d) and correct recombination of the lox allele (L) in GSvECKO and 1384 
GSpECKO mice upon tamoxifen (tam) treatment, as assessed by genomic DNA PCR (e; the 1385 
PCR to amplify the loxed GS allele (lox) or to amplify the Cre-recombined allele (¨) were 1386 
run in separate reactions but loaded in the same lane; the gel picture shown is 1387 
representative for all control, vECKO and pECKO mice used in this study). f, Quantification 1388 
of branchpoints at the rear of the plexus in GSvECKO mice (mean±s.e.m.; n=10 animals for 1389 
GSvECKO and 11 for wild-type (WT) controls from 3 litters; *P<0.05 vs WT littermates, mixed 1390 
models R statistics). g, Pericyte coverage of retinal microvessels in WT and GSvECKO 1391 
littermates determined by NG2 staining and shown as NG2+ area as % of vessel area 1392 
(mean±s.e.m.; n=4 animals for WT and 3 for GSvECKO from 1 litter; NSP>0.05 vs WT, 1393 
Students t test). h, Reduced complexity of the retinal vascular front in P5 GSvECKO vs WT 1394 
animals determined by the number of branches on distal sprouts (mean±s.e.m.; n=13 1395 
animals for WT and 21 for GSvECKO from 5 litters; *P<0.05 vs WT, Students t test). i, 1396 
Quantification of EdU+ ECs at the rear of the plexus (mean±s.e.m.; n=12 animals for WT 1397 
and 22 for GSvECKO from 4 litters; NSP>0.05 vs WT littermates, Students t test). j-m, 1398 
Isolectin B4 staining of P5 retinal vascular plexi from WT (j) and GSpECKO (k) mice 1399 
(representative pictures with zoom-in insets, A=artery, V=vein) and quantification of branch 1400 
points at the front (l) and the rear (m) of the plexus (mean±s.e.m.; n=10 animals for WT 1401 
and 18 for GSpECKO from 4 litters; *P0.05 vs WT littermates, Students t test). n-u, 1402 
Isolectin B4 staining of the retinal microvasculature of 3 week (P21)-old (n,o) and 6 week 1403 
(P42)-old (r,s) WT and GSvECKO littermates (A=artery, V=vein). Lower left insets display 1404 
higher magnification of IB4-stained superficial plexus, whereas lower right insets display 1405 
higher magnification of the deep plexus. Also shown is the corresponding quantification of 1406 
the vascular area (p,t) and the branch point density (q,u) in the superficial and the deep 1407 
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layer  (mean±s.e.m.; n=8 animals for WT and 8 for GSvECKO at P21, from two litters; n=10 1408 
animals for WT and 14 for GSvECKO at P42, from four litters; NSP>0.05 vs WT, Students t 1409 
test). v-ag, Representative micrographs of heart (v,z), liver (w,aa) and kidney (x,ab) 1410 
sections from WT and GSvECKO littermates immunostained for the EC marker endoglin and 1411 
of lung (y,ac) sections immunostained for the EC marker CD34 and corresponding 1412 
quantifications of endoglin+ (ad, heart; ae, liver; af, kidney) or CD34+ (ag) vascular area 1413 
(mean±s.e.m.; n=5 animals (4 for heart) for WT and 7 (6 for heart) for GSvECKO, from two 1414 
litters, NSP>0.05 vs WT, Students t test). ah-ai, Images of flat-mounted retinas from 1415 
control (ah) and MSO-treated (ai) ROP mice (vaso-obliterated area in white). Images 1416 
shown are representative for 7 (ah) and 6 (ai) mice. Exact P values: (a) HUVEC vs lung 1417 
ECs: 0.0278; HUVEC vs colon ECs: 0.1086; HUVEC vs liver ECs: 0.3334; HUVEC vs 1418 
HEPG2: <0.0001; (f) <0.0001; (g) 0.3491; (h) <0.0001; (i) 0.8247; (l) 0.0012; (m) 0.050; (p) 1419 
superficial: 0.1218; deep: 0.1720; (q) superficial: 0.9995; deep: 0.4289; (t) superficial: 1420 
0.9792; deep: 0.6602; (u) superficial: 0.7979; deep: 0.1275; (ad) 0.9021; (ae) 0.2279; (af) 1421 
0.7647; (ag) 0.3614. Scale bars are 200 µm in j-k, n-o and r-s, 20 µm in v-ac and 1 mm in 1422 
ah-ai. HEPG2: hepatocellular carcinoma cells; mLiEC: mouse liver ECs; Tam: tamoxifen; 1423 
lox: loxed allele; ǻ: recombined allele; NG2: chondroitin sulfate proteoglycan 4; Edu: 5-1424 
ethynyl-2'-deoxyuridine. For gel source images, see Supplemental Information Fig. 1. 1425 
 1426 
EXTENDED DATA FIGURE 2: EFFECTS OF SILENCING AND PHARMACOLOGICAL INHIBITION 1427 
OF GS ON EC VIABILITY AND CENTRAL METABOLISM  1428 
a, GS mRNA levels in control ECs and ECs transduced with two different non-overlapping 1429 
shRNAs targeting GS (GSKD1 and GSKD2; GSKD1 is used in the experiments in the main 1430 
manuscript and denoted as GSKD) or transfected with scrambled siRNA (SCR) or siRNA 1431 
targeting GS (siGS). Data are expressed as % of the respective control, denoted by the 1432 
horizontal dotted line (mean±s.e.m.; n=28 independent experiments for GSKD1, n=3 1433 
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independent experiments for GSKD2 and n=9 independent experiments for siGS; *P<0.05 1434 
vs the respective control; one sample t test). b-c, Quantification of number of sprouts (b) 1435 
and total sprout length (c) for spheroid sprouting assays with GSKD ECs and GSKD ECs 1436 
expressing a shRNA-resistant GS mutant (rGSOE) (mean±s.e.m.; n=3 independent 1437 
experiments; *P<0.05 and NSP>0.05 vs control; ANOVA with Dunnetts multiple 1438 
comparison vs control). d, Viability of control and GSKD ECs as measured by lactate 1439 
dehydrogenase (LDH) release assay (mean±s.e.m.; n=3 independent experiments; 1440 
NSP>0.05 vs control, one sample t test). e, Intracellular reactive oxygen species (ROS) 1441 
levels measured by CM-H2DCFDA staining (mean±s.e.m.; n=3 independent experiments; 1442 
NSP>0.05 vs control, Students t test). f, Energy charge measurement (([ATP] + 1Ú2[ADP]) / 1443 
([ATP] + [ADP] + [AMP])) in GSKD and control ECs (mean±s.e.m.; n=3 independent 1444 
experiments; NSP>0.05 vs control, Students t test). g, Ratio of oxidized glutathione over 1445 
total glutathione levels (GSSG/(GSH+GSSG)) in GSKD and control ECs (mean±s.e.m.; n=4 1446 
independent experiments; NSP>0.05 vs control, Students t test). h, NADP/NADPH ratio in 1447 
GSKD and control ECs (mean±s.e.m.; n=5 independent experiments; NSP>0.05 vs control, 1448 
one sample t test). i-k, Effect of GSKD on major metabolic fluxes including glycolysis (i), 1449 
glucose oxidation (j) and glutamine oxidation (k) (mean±s.e.m.; n=3 independent 1450 
experiments for (i), n=5 for (j) and n=4 for (k); NSP>0.05 vs control, one sample t test). l,m, 1451 
Oxygen consumption rate (OCR) in control, MSO-treated and GSKD ECs in basal state and 1452 
after injection of oligomycin, FCCP and antimycin A (l) (mean±s.e.m.; n=3 independent 1453 
experiments), and calculation of OCRBAS, OCRATP and maximal respiration (m) 1454 
(mean±s.e.m.; n=3 independent experiments). Exact P values: (a) GSKD1: <0.0001; GSKD2: 1455 
<0.0001; siGS: <0.0001; (b) ctrl vs GSKD: 0.0147; ctrl vs GSKD + rGSOE: 0.9824; (c) ctrl vs 1456 
GSKD: 0.0083; ctrl vs GSKD + rGSOE: 0.6528; (d) 0.5717; (e) 0.8206 ; (f) 0.3715; (g) 0.4398; 1457 
(h) 0.9291; (i) 0.4691 (j) 0.6643 (k) 0.6786. AU: arbitrary units; CM-DCF: 5-(and-6)-1458 
chloromethyl-2ƍ,7ƍ-dichlorodihydrofluorescein diacetate, acetyl ester; FCCP: carbonyl 1459 
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cyanide-4-(trifluoromethoxy) phenylhydrazone; OCRBAS: basal oxygen consumption rate; 1460 
OCRATP: ATP-generating oxygen consumption rate; RFU: relative fluorescence units; 1461 
MSO, methionine sulfoximine. 1462 
 1463 
EXTENDED DATA FIGURE 3: GS KNOCK-DOWN REDUCES EC MOTILITY 1464 
a, Wound closure in control and GSKD2 EC monolayer scratch assays with or without 1465 
MitoC-pretreatment (mean±s.e.m.; n=7 and 5 independent experiments for with and 1466 
without MitoC respectively; *P<0.05 vs corresponding control; Students t test). b, 1467 
Quantification of lamellipodial area (% of total cellular area) in control and GSKD2 ECs 1468 
(mean±s.e.m.; n=3 independent experiments; *P<0.05 vs control; Students t test). c, 1469 
Wound closure in monolayer scratch assays with SCR- and siGS-transfected ECs 1470 
(mean±s.e.m.; n=5 independent experiments; *P<0.05 vs SCR; Students t test). d, 1471 
Quantification of lamellipodial area (% of total cellular area) in SCR- and siGS-transfected 1472 
ECs (mean±s.e.m.; n=5 independent experiments; *P<0.05 vs SCR; Students t test). e, 1473 
[3H]-Thymidine incorporation into DNA in SCR- and siGS-transfected ECs (mean±s.e.m.; 1474 
n=3 independent experiments; NSP>0.05 vs SCR; Students t test). Exact P values: (a) ctrl 1475 
vs GSKD2: 0.0290; ctrl vs GSKD2 + MitoC: 0.0223; (b) 0.0088; (c) 0.0407; (d) 0.0083; (e) 1476 
0.4335. 1477 
 1478 
EXTENDED DATA FIGURE 4: EFFECTS OF GS SILENCING ON CYTOSKELETON AND 1479 
BARRIER FUNCTION 1480 
a-h, Images of control (a,c,e,g) and GSKD (b,d,f,h) ECs after staining for α-tubulin (a,b), F-1481 
actin (c,d) and nuclear staining (e,f); images shown are representative for 3 independent 1482 
experiments.  i-k, Representative images of phalloidin + Hoechst-stained liver ECs 6 hours 1483 
after isolation from control (i) and MSO-treated (j) mice, and corresponding quantification 1484 
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of F-actin levels (k) (mean±s.e.m.; n=5 mice per group; *P<0.05 vs control, Students t 1485 
test). l-n, Representative images of phalloidin-stained (F-actin) confluent monolayer 1486 
control (l) and GSKD (m) ECs aligning a scratch wound, and quantification of F-actin levels 1487 
(n) (mean±s.e.m.; n=5 independent experiments; *P<0.05 vs control, Students t test). o, 1488 
Quantification of the length of discontinuous and continuous VE-cadherin-stained junctions 1489 
in control and GSKD ECs (mean±s.e.m.; n=4 independent experiments; *P<0.05 vs control, 1490 
Students t test). p, Quantification of VE-cadherin gap size index in control and GSKD EC 1491 
monolayers (mean±s.e.m.; n=4 independent experiments; *P<0.05 vs control, Students t 1492 
test). q-v, Corresponding representative images of monolayer control and GSKD ECs 1493 
stained for VE-cadherin (q,r,u,v) and F-actin (s,t,u,v). Yellow arrows in (r) point to 1494 
discontinuous VE-cadherin junctions and yellow asterisks indicate intracellular gaps. w, 1495 
Quantification of transendothelial electrical resistance (TEER) in control and GSKD EC 1496 
monolayers (mean±s.e.m.; n=4 independent experiments; *P<0.05 vs control, Students t 1497 
test at each time point). x-z, Quantification (x) of Evans blue dye extracted from the ears of 1498 
control and MSO-treated mice induced by topical application of mustard oil (n=4 mice for 1499 
each condition, *P<0.05; Students t test) and representative pictures of the Evans blue 1500 
leakage into the ear tissue in control (y) and MSO-treated (z) mice. Exact P values: (k) 1501 
0.0030; (n) 0.0036; (o) continuous ctrl vs GSKD: 0.0005; discontinuous ctrl vs GSKD: 1502 
0.0005; (p) 0.0356; (w) 0.0181; (x) 0.0002. Scale bar is 20 µm in a-h and in l-m and 10 µm 1503 
in i-j and in q-v. AU: arbitrary units. 1504 
 1505 
EXTENDED DATA FIGURE 5: ENZYMATIC ACTIVITY OF GS AND ITS ROLE IN EC MIGRATION 1506 
a, Scheme of 15NH4
+ labeling of glutamate and glutamine with unlabeled carbons (blue) 1507 
and labeled nitrogens (red). b, 15N incorporation into glutamine (% isotope enrichment in 1508 
m+1 and m+2, 30 min after adding 15NH4
+) in medium with dialyzed serum and different 1509 
glutamine concentrations (mean±s.e.m.; n=3 independent experiments; ANOVA with 1510 
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Dunnetts multiple comparisons vs 4 mM; *P <0.05). c, 15N incorporation into glutamate (% 1511 
isotope enrichment in m+1) and glutamine (% isotope enrichment in m+1 and m+2), 30 1512 
min after adding increasing concentrations of 15NH4Cl (mean±s.e.m.; n=3 independent 1513 
experiments). d, Scheme of glutamine labeling from [U-13C]-glutamate with unlabeled 1514 
nitrogens (blue) and labeled carbons (red). e, Label contribution of [U-13C]-glutamate to 1515 
intracellular glutamine at various glutamine concentrations (% isotope enrichment in 1516 
glutamine and glutamate m+5, 30 min after adding the tracer) (mean±s.e.m.; n=3 1517 
independent experiments; ANOVA with Dunnetts multiple comparisons vs 4 mM; *P 1518 
<0.05). f, Scheme for [U-13C]-glucose carbon contribution to glutamine with labeled 1519 
carbons (red) and unlabeled carbons (blue). Incorporation is shown after one turn of the 1520 
TCA cycle. g, Total contribution of [U-13C]-glucose carbons to α-ketoglutarate, glutamate 1521 
and glutamine in ECs in medium with or without glutamine, 48 h after adding the tracer 1522 
(mean±s.e.m.; n=3 independent experiments; *P<0.05 vs total contribution in Gln at 0.6 1523 
mM external Gln, ANOVA with Dunnetts multiple comparisons). h, 15N incorporation into 1524 
glutamine (% isotope enrichment in m+1 and m+2, 30 min after adding 15NH4
+) in ECs and 1525 
HEPG2 cells (mean±s.e.m.; n=4 independent experiments (ND=not detected)). i, 13C-1526 
glutamine uptake kinetics in control, MSO-treated and GSKD ECs and subsequent 1527 
conversion to glutamate. See Methods for explanation of the different time points. Data are 1528 
expressed as m+5 isotopomer, as percentage of the total intracellular glutamine (gln) or 1529 
glutamate (glu) pool (mean±s.e.m.; n=3 independent experiments, except for 30 min 1530 
where n=1 experiment; no statistical differences between control, MSO-treated and GSKD 1531 
were observed for glutamine nor for glutamate; ANOVA with Dunnetts multiple 1532 
comparison vs control at each time point; no statistical analysis was performed at 30 min). 1533 
j, 14C-glutamine uptake in control and GSKD ECs (mean±s.e.m.; n=5 independent 1534 
experiments; NSP>0.05 vs control, one sample t test). k, Ratio of intracellular glutamine 1535 
(Gln) over glutamate (Glu) levels in control and GSKD ECs (mean±s.e.m.; n=3 independent 1536 
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experiments; NSP>0.05 vs control, Students t test). l, Velocity measurement of control and 1537 
GSKD ECs at different glutamine (Gln) concentrations (mean±s.e.m.; n=4 independent 1538 
experiments; *P<0.05 vs corresponding control, mixed models R statistics). m-n, Effect of 1539 
glutamine concentration on sprout number (m) and total sprout length (n) in control and 1540 
GSKD spheroids (mean±s.e.m.; n=3 independent experiments; *P <0.05 vs corresponding 1541 
control, mixed models R statistics). o-p, Number of sprouts per spheroid (o) and total 1542 
sprout length (p) in control and MSO-treated EC spheroids (mean±s.e.m.; n=3 1543 
independent experiments; *P<0.05 vs control, paired Students t test). q-s, Effect of MSO-1544 
treatment on EC motility parameters: wound closure of MitoC-treated ECs (q) 1545 
(mean±s.e.m.; n=11 independent experiments; *P<0.05 vs control, Students t test), 1546 
lamellipodial area (r) (mean±s.e.m.; n=10 independent experiments; *P<0.05 vs control, 1547 
paired Students t test) and F-actin levels, 1 h after latrunculin wash-out (s) (mean±s.e.m.; 1548 
n=4 independent experiments; *P<0.05 vs control, one-sample t test). t, [3H]-Thymidine 1549 
incorporation in control and MSO-treated ECs (mean±s.e.m.; n=3 independent 1550 
experiments; NSP>0.05 vs control, one sample t test). Exact P values: (b) m+1 0.025 mM 1551 
vs m+1 4 mM: 0.0096; m+1 0.6 mM vs m+1 4 mM: 0.1206; m+2 0.025 mM vs m+2 4 mM: 1552 
0.0839; m+2 0.6 mM vs m+2 4 mM: 0.9921; (e) Glu m+5 0.6 mM vs Glu m+5 4 mM: 1553 
0.9372; Glu m+5 0.025 mM + MSO vs Glu m+5 4 mM: 0.0034; Glu m+5 0.025 mM vs Glu 1554 
m+5 4 mM: 0.0215; Gln m+5 0.6 mM vs Gln m+5 4 mM: 0.9297; Gln m+5 0.025 mM + 1555 
MSO vs Gln m+5 4 mM: 0.9961; Gln m+5 0.025 mM vs Gln m+5 4 mM: 0.0268; (g) α-keto 1556 
0.6 mM vs Gln 0.6 mM: 0.0001; Glu 0.6 mM vs Gln 0.6 mM: 0.0001; Gln 0 mM vs Gln 0.6 1557 
mM: 0.0285; (i) Gln 0.5 min: ctrl vs MSO: 0.4846; ctrl vs GSKD: 0.5904; Gln 10 min: ctrl vs 1558 
MSO: 0.6709; ctrl vs GSKD: 0.6910; Gln 20 min: ctrl vs MSO: 0.5896; ctrl vs GSKD: 0.6784; 1559 
Glu 0.5 min: ctrl vs MSO: 0.9774; ctrl vs GSKD: 0.8810; Glu 10 min: ctrl vs MSO: 0.0502; 1560 
ctrl vs GSKD: 0.9598; Glu 20 min: ctrl vs MSO: 0.9782; ctrl vs GSKD: 0.7783. (j) 0.6623; (k) 1561 
0.6704; (l) ctrl vs GSKD 0.1 mM: 0.0054; ctrl vs GSKD 0.6 mM: 0.0247 ctrl vs GSKD 2 mM: 1562 
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0.0017; (m) ctrl vs GSKD 0.6 mM and 10 mM: < 0.0001; (n) ctrl vs GSKD 0.6 mM and 10 1563 
mM: < 0.0001; (o) 0.0313; (p) 0.0075; (q) 0.0019; (r) 0.0116; (s) 0.0091; (t) 0.5110. α-keto: 1564 
α-ketoglutarate; GDH: glutamate dehydrogenase; Glu: glutamate; GS: glutamine 1565 
synthetase; Gln: glutamine; MSO, methionine sulfoximine; MitoC: mitomycin C. 1566 
 1567 
EXTENDED DATA FIGURE 6: RESCUING THE GSKD PHENOTYPE IN VITRO 1568 
a, Schematic representation of the DORA RHOA FRET biosensor, depicting from N- to C-1569 
terminal the circular permutated RHOA effector protein kinase N (cpPKN), the dimeric 1570 
circular permutated Venus (dcpVen), the ribosomal protein-based linkers (L9), the dimeric 1571 
Cerulean3 (dCer3) and RHOA. b-m, Representative images of control (b-d), MSO-treated 1572 
(e-g), GSKD (h-j) and RHOJKD (k-m) ECs after staining for F-actin (phalloidin) 1573 
(b,d,e,g,h,j,k,m) and pMLC (c,d,f,g,i,j,l,m). n, Quantification of the pMLC-immunoreactivity 1574 
(mean±s.e.m.; n=5 independent experiments; *P<0.05 vs control, one sample t test). o-t, 1575 
Representative images of control (o,q,s) and GSKD (p,r,t) EC spheroids treated with vehicle 1576 
(o,p) or the ROCK inhibitors Y27632 (q,r) or fasudil hydrochloride (s,t). u-v, Quantification 1577 
of the number of sprouts per spheroid (u) and sprout length (v) (mean±s.e.m.; n=3 1578 
independent experiments; *P<0.05 and NSP>0.05 vs untreated control, ANOVA with 1579 
Dunnetts multiple comparisons vs untreated control). w, Quantification of the lamellipodial 1580 
area in vehicle- or fasudil hydrochloride-treated control and GSKD ECs (mean±s.e.m.; n=6 1581 
independent experiments; *P<0.05 and NSP>0.05 vs untreated control, ANOVA with 1582 
Dunnetts multiple comparisons vs untreated control). x, Quantification of the lamellipodial 1583 
area in vehicle-, ML7- or peptide 18-treated GSKD and control ECs (mean±s.e.m.; n=4 1584 
independent experiments of which 3 experiments included the ML7-treatment; *P<0.05 vs 1585 
untreated control, ANOVA with Dunnetts multiple comparisons vs untreated control). y, 1586 
Scratch wound closure in vehicle-, ML7- or peptide 18-treated GSKD and control ECs 1587 
(mean±s.e.m.; n=3 independent experiments; *P<0.05 vs untreated control, ANOVA with 1588 
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Dunnetts multiple comparisons vs untreated control). z, Fold-changes (vs untreated 1589 
control ECs) in F-actin levels from phalloidin-stained vehicle-, ML7- or peptide 18-treated 1590 
GSKD ECs (mean±s.e.m.; n=4 independent experiments of which 3 included the peptide 1591 
18-treatment; *P<0.05 vs untreated control, one sample t test). aa, Fold-changes (vs 1592 
untreated control ECs) in pMLC levels from pMLC-immunostained vehicle-, ML7- or 1593 
peptide 18-treated GSKD ECs (mean±s.e.m.; n=4 independent experiments of which 3 1594 
included the peptide 18-treatment; *P<0.05 vs untreated control, one sample t test. Exact 1595 
P values: (n) MSO: 0.0372; GSKD: 0.0060; RHOJKD: 0.0051; (u) GSKD vs ctrl: 0.0045; Fasu 1596 
vs ctrl: 0.9596; GSKD + Fasu vs ctrl: 0.8857; (v) GSKD vs ctrl: 0.0199; Fasu vs ctrl: 0.8309; 1597 
GSKD + Fasu vs ctrl: 0.9327; (w) GSKD vs ctrl: 0.0074; Fasu vs ctrl: 0.5906; GSKD + Fasu 1598 
vs ctrl: 0.9900; (x) GSKD vs ctrl: 0.0011; GSKD + ML7 vs ctrl: 0.0079; GSKD + pep.18 vs ctrl: 1599 
0.0017; (y) GSKD vs ctrl: 0.0034; GSKD + ML7 vs ctrl: 0.0022; GSKD + pep.18 vs ctrl: 1600 
0.0040; (z) GSKD: 0.0058; ML7: 0.0072; pep.18: 0.0888; (aa) GSKD: 0.0369; ML7: 0.0021; 1601 
pep.18: 0.1672. Fasu., fasudil hydrochloride; pep. 18, peptide 18. Scale bar is 20 µm in (b-1602 
m) and 100 µm in (o-t). For gel source images, see Supplemental Information Fig. 1. 1603 
 1604 
EXTENDED DATA FIGURE 7: RHOGTPASE LOCALIZATION AND INTERACTION WITH GS 1605 
a, Co-IP assays showing no detectable interaction between GS and RHOA or RHOC (red 1606 
asterisk indicates a non-specific band (also present in the IgG controls and unaffected by 1607 
silencing of RHOA or RHOC). Picture shown is representative for 3 independent 1608 
experiments. b, Co-IP of overexpressed GS and RHOJ-EGFP or ΔN-RHOJ-EGFP in ECs. 1609 
Quantifications are mean±s.e.m.; n=4 independent experiments; *P<0.05, one-sample t 1610 
test. In some of the experiments, the expression of ΔN20-RHOJ-EGFP was lower than 1611 
expression of RHOJ-EGFP. To correct for this, densitometric quantification was performed 1612 
and signals in IP lanes were normalized to input signals. c, Immunoblotting for RHOA and 1613 
RHOC on cytosolic (c) and membrane (m) fractions of ECs with NaK as membrane marker 1614 
7/18/2018 63
and GAPDH as cytosolic marker. Picture shown is representative for 3 independent 1615 
experiments. d, Bimolecular fluorescence complementation (BiFC) assay with GS coupled 1616 
to the N-terminal half of EGFP, and RHOJ coupled to the C-terminal half of EGFP. Only 1617 
when GS and RHOJ are in close proximity, the two EGFP half-sites complement each 1618 
other and form a functional EGFP. e, Percentage of ECs displaying BiFC upon 1619 
overexpression of GS-EGFP1/2 and RHOJ-EGFP2/2 or GS-EGFP1/2 and ǻN-RHOJ-1620 
EGFP2/2. Data are mean±s.e.m.; n=3 independent experiments; *P<0.05; Students t test. 1621 
f, Scheme for SPT-PALM imaging under TIRF illumination with the plasma membrane 1622 
depicted at the top. The TIRF region is bright (whereas the part outside the TIRF region is 1623 
grayed out) and contains the plasma membrane and its immediately adjacent space (not 1624 
shown at exact relative dimensions). Weight and number of arrowheads represent velocity 1625 
of single particles (the photoswitchable fluorescent protein (PSFP) or the PSFP coupled to 1626 
the protein of interest (here GS)). The PSFP is activated upon entry into the TIRF region 1627 
and is color-coded differently inside vs outside of the TIRF region. PSFP-GS displays 1628 
reduced velocity in the TIRF region, presumably because of palmitoylation and membrane 1629 
association of GS. g, Scheme for in-cell labeling of proteins with clickable alkyne-1630 
containing palmitoylation probes and subsequent biotin-azide clicking. X represents a 1631 
palmitoylated protein, N3
 is the biotin-coupled azide. h-i, Rate of CoA release from 1632 
palmitoyl-CoA as readout for recombinant human GS autopalmitoylation while varying 1633 
either the doses of palmitoyl-CoA (h) or the amounts of recombinant GS (i) (mean±s.e.m.; 1634 
n=4 independent experiments for h and n=5 for i; *P<0.05, ANOVA with Dunnetts multiple 1635 
comparisons vs 0 µM palmitoyl-CoA or vs 0.5 µg recombinant GS). j, Representative GS 1636 
immunoblot (of 3 independent experiments) for binding of recombinant human GS to 1637 
palmitoyl-CoA agarose. IF=input fraction; FT=flow through; W8=wash fraction 8; 1638 
SDS=eluate. k-m, Representative images of RHOJ-EGFP localization in ECs under 1639 
vehicle-treatment (k) or treatment with 2BP (pan-palmitoylation inhibitor) (l). Red 1640 
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arrowheads indicate EGFP signal at membrane ruffles, which was quantified as percent of 1641 
total cellular area (m) (mean±s.e.m.; n=4 independent experiments; *P<0.05 vs vehicle-1642 
treated, paired Students t test). n-p, Representative images of ECs overexpressing wt 1643 
RHOJ-EGFP (n), RHOJ-EGFP point-mutated on cysteine residue 3 (C3A) (o) or RHOJ-1644 
EGFP point-mutated on cysteine residue 11 (C11A) (p). Red arrowheads indicate RHOJ at 1645 
the plasma membrane. ECs that are not completely in the field of view have been masked 1646 
out in blue. q, Quantification of the RHOJ-EGFP positive area at the plasma membrane as 1647 
a percentage of total cell area. Data are mean±s.e.m.; n=5 independent experiments; 1648 
*P<0.05; ANOVA with Dunnetts comparison vs wt RHOJ. r, RHOJ immunoblotting on 1649 
membrane vs cytosolic fractions from ECs overexpressing wt RHOJ-EGFP (RHOJ WT), 1650 
RHOJ-EGFP point-mutated on cysteine residue 3 (RHOJ C3A) or RHOJ-EGFP point-1651 
mutated on cysteine residue 11 (RHOJ C11A), with NaK as membrane marker and 1652 
GAPDH and Į-tubulin as cytosolic markers. s, Densitometric quantification of RHOJ/NaK 1653 
as determined in (r). Data are mean±s.e.m.; n=6 independent experiments; *P<0.05; one 1654 
sample t test. t, RHOJ activity in ECs under vehicle- or 2BP-treatment (blots are 1655 
representative of 3 independent experiments; densitometric quantification in arbitrary units 1656 
(AU) is mean±s.e.m; *P<0.05, paired Students t test vs vehicle-treated). u, RHOJ 1657 
immunoblotting for control and GSKD ECs overexpressing RHOJ (RHOJOE) subjected to 1658 
acyl-RAC. The cleaved bound fraction (cBF) represents palmitoylated RHOJ. IF is the 1659 
input fraction, whereas the cleaved unbound fraction (cUF) and the preserved bound 1660 
fraction (pBF) are controls showing depletion of RHOJ from the thioester cleaving reagent 1661 
and near absence of non-specific binding of RHOJ to the resin (see Methods). 1662 
Densitometric quantification of cBF/IF is shown (mean±s.e.m; n=3 independent 1663 
experiments; *P<0.05, one-sample t test vs control). v, GRAPHICAL ABSTRACT: Left side: 1664 
Autopalmitoylation allows endothelial GS to interact directly (or indirectly) with the 1665 
RhoGTPase RHOJ and to sustain RHOJs palmitoylation, membrane localization and 1666 
7/18/2018 65
activity (reflected by GTP binding). RHOJ activity then sustains normal EC migration and 1667 
lamellipodia formation, and keeps actin stress fiber formation at levels, promoting normal 1668 
EC migration and vessel branching in vivo. Through mechanisms that are incompletely 1669 
understood, active RHOJ inhibits signaling of the RHOA/B/C  ROCK  (p)MLC pathway 1670 
(itself known to promote stress fiber formation). The relative contribution of a direct effect 1671 
of RHOJ on migration vs the indirect effect through RHOA/B/C  ROCK  (p)MLC remains 1672 
to be determined.  Reduced opacity of RHOA/B/C, ROCK and (p)MLC indicates reduced 1673 
signaling of this pathway. GTP: guanosine triphosphate. Right side: Loss of endothelial GS 1674 
renders RHOJ less active (visually reflected by fewer palmitoylated, membrane-bound 1675 
RHOJ proteins), and weakens the brake on the RHOA/B/C  ROCK  (p)MLC pathway. 1676 
The resulting excessive stress fiber formation causes ECs to lose migratory capacity and 1677 
reduces vessel branching in vivo. Dashed lines indicate reduced activity; red X indicates 1678 
GS blockade; question mark indicates unknown mechanisms. Exact P values: (b) 0.0153; 1679 
(e) 0.0334; (h) 2 vs 0 µM: 0.6327; 5 vs 0 µM: 0.2841; 10 vs 0 µM: 0.1090; 20 vs 0 µM: 1680 
0.0339; 40 vs 0 µM: 0.0034; (i) 1 vs 0.5 µg:  0.5806; 2 vs 0.5 µg: 0.0319; 4 vs 0.5 µg 1681 
:0.0037; 8 vs 0.5 µg: 0.0001; 16 vs 0.5 µg: 0.0001; (m) 0.0313; (q) RHOJ C3A vs RHOJ 1682 
WT: 0.0001; RHOJ C11A vs RHOJ WT: 0.0001; (s) RHOJ C3A vs RHOJ WT: 0.0015; 1683 
RHOJ C11A vs RHOJ WT: 0.0007; (t) 0.0051; (u) 0.0461. Scale bar is 200 µm in k,l,n-p. 1684 
For gel source images, see Supplemental Information Fig. 1. 1685 
 1686 
EXTENDED DATA FIGURE 8: POSSIBLE MOLECULAR MODEL OF GS AUTOPALMITOYLATION 1687 
a. Structure of human GS and of its bifunnel-shaped catalytic site. Schematic 1688 
representation of the GS decamer in top and front view with individual subunits A and B 1689 
labeled and colored gray and green, respectively. Close-up of the bifunnel catalytic site 1690 
which is formed between subunits A and B. The GS decamer has 10 active sites, each 1691 
located at the interface of two adjacent subunits. ATP enters from the top whereas 1692 
7/18/2018 66
glutamate enters from below; Manganese ions (Mn2+) are shown as metalic spheres. b. 1693 
Molecular dynamics (MD) simulation of palmitoyl-CoA in the catalytic cleft of GS predicts 1694 
that, while the head of palmitoyl-CoA is tightly bound to the adenine binding site, the tail 1695 
can point in opposing directions with respect to the proteins principal axis. The most 1696 
representative structures of the two alternative poses observed during the long MD 1697 
simulations for palmitoyl-CoA binding to GS (in blue, seen from two different perspectives) 1698 
are shown in red (A, tail bending upwards) and green (B, tail bending downwards). c. 1699 
Detailed view on the main conformation  conformation A  is shown in more details. The 1700 
sulfur atom of palmitoyl-CoA (which is immediately adjacent to the carbon on which the 1701 
nucleophilic attack occurs) (colored yellow) approaches the highly conserved C209 (also 1702 
colored yellow), with an interatomic distance (S-S) that during the simulations reversibly 1703 
fluctuates between 3 and 8 Å. The hydrophobic tail positions itself along grooves 1704 
characterized by the presence of hydrophobic residues. Color coding: carbons are grey, 1705 
nitrogens blue, phosphorous golden and oxygens red. Cysteines and serines within 5 Å 1706 
from the palmitoyl tail are highlighted in yellow and orange, respectively. The hydrophobic 1707 
residues around the tail are shown in green. d. Detailed view on conformation B where the 1708 
tail is found in a buried hydrophobic cleft, with the sulfur at a distance of 5 Å or less from 1709 
the conserved serines 65 and 75 and the tail occupying the site of the GS inhibitor MSO. 1710 
Details are shown of the extensive steric clash between MSO and the secondary binding 1711 
pose (B) observed in palmitoyl-CoA MD simulations. Palmitoyl-CoA is represented as 1712 
sticks with standard atomic colours. MSO is shown in cyan and its position is taken from 1713 
the 2QC8 entry in the protein databank. Cysteines and serines within 5 Å from the 1714 
palmitoyl tail are highlighted in yellow and orange, respectively. The hydrophobic residues 1715 
around the tail are shown in green. e. GS immunoblotting after streptavidin pull-down of 1716 
biotin-azide clicked lysates from 16C-YA (palmitoylation probe) labeled HEK-293T cells 1717 
overexpressing wild type GS or GS point-mutated for C209. The input shows the level of 1718 
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GS overexpression. Representative blot for 4 independent experiments is shown. f-g. 1719 
Quantification of total sprout length (f) and number of sprouts per spheroid (g) for control 1720 
and GSKD ECs with or without overexpression of shRNA resistant C209A-point mutated 1721 
GS (rGSC209A-OE) (mean ± s.e.m.; n=4 independent experiments; *P <0.05 vs control, 1722 
ANOVA with Dunnetts multiple comparison vs control). h. Schematic representation of 1723 
protein autopalmitoylation. Upon binding of palmitoyl-CoA to the protein, free CoA (gray 1724 
oval) is released and can be detected. i. Recombinant wild-type (WT) and point-mutated 1725 
(R324C and R341C) GS were incubated with different doses of palmitoyl-CoA in a cell-free 1726 
system at physiologcial pH. Release of CoA per minute was determined as a direct 1727 
readout for protein autopalmitoylation. Data are mean ± s.e.m. of 3 (R324C and R341C) 1728 
and 4 (WT) independent experiments. NSP>0.05; *P<0.05 according to two way ANOVA 1729 
comparing the entire dose-response to the dose-response of WT GS.  j. Different amounts 1730 
of recombinant WT, R324C and R341C GS were incubated with a fixed amount of 1731 
palmitoyl-CoA (40 ȝM) and CoA release per minute was determined as readout for 1732 
autopalmitoylation. Data are mean ± s.e.m. of 4 (R324C and R341C) and 5 (WT) 1733 
independent experiments. NSP>0.05; *P<0.05 according to two way ANOVA comparing the 1734 
entire dose-response to the dose-response of WT GS. The data for WT GS from panels (i) 1735 
and (j) are also included in Extended Data Fig. 7 as stand-alone data, but are included 1736 
here too for comparison purposes. k. Boyden chamber migration for control, GSKD, GSKD + 1737 
rGSOE (r = shRNA-resistant; OE = overexpression), GSKD + rGSR341C-OE and GSKD + 1738 
rGSR324C-OE ECs, all under mitomycin C-treatment (mean ± s.e.m.; n=3 independent 1739 
experiments; NSP>0.05; *P<0.05, ANOVA with Dunnetts multiple comparison vs control). 1740 
Exact P values: (f) GSKD vs ctrl: 0.0004; GSKD + rGSC209A-OE vs ctrl: 0.0004; (g) GSKD vs 1741 
ctrl: 0.0001; GSKD + rGSC209A-OE vs ctrl: 0.0001; (i) R324C vs WT: 0.8228; R341C vs WT: 1742 
0.7530; (j) R324C vs WT: 0.1331; R341C vs WT: 0.0003; (k) GSKD vs ctrl: 0.0054; GSKD + 1743 
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rGSOE vs ctrl: 0.8152; GSKD + rGSR341C-OE vs ctrl: 0.3645; GSKD + rGSR324C-OE vs ctrl: 1744 
0.2118. For gel source images, see Supplemental Information Fig. 1. 1745 
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